STATE-OF-THE-ART REVIEW

The two faces of cyanide: an environmental toxin and a potential novel mammalian gasotransmitter

Karim Zuhra [ID] and Csaba Szabo [ID]

Chair of Pharmacology, Section of Medicine, University of Fribourg, Switzerland

Cyanide is traditionally viewed as a cytotoxic agent, with its primary mode of action being the inhibition of mitochondrial Complex IV (cytochrome c oxidase). However, recent studies demonstrate that the effect of cyanide on Complex IV in various mammalian cells is biphasic: in lower concentrations (nanomolar to low micromolar) cyanide stimulates Complex IV activity, increases ATP production and accelerates cell proliferation, while at higher concentrations (high micromolar to low millimolar) it produces the previously known ('classic') toxic effects. The first part of the article describes the cytotoxic actions of cyanide in the context of environmental toxicology, and highlights pathophysiological conditions (e.g., cystic fibrosis with *Pseudomonas* colonization) where bacterially produced cyanide exerts deleterious effects to the host. The second part of the article summarizes the mammalian sources of cyanide production and overviews the emerging concept that mammalian cells may produce cyanide, in low concentrations, to serve biological regulatory roles. Cyanide fulfills many of the general criteria as a 'classical' mammalian gasotransmitter and shares some common features with the current members of this class: nitric oxide, carbon monoxide, and hydrogen sulfide.

Introduction

Cyanide is endogenously produced in organisms from many kingdoms including bacteria, fungi, arthropods, and plants. In these organisms, cyanide serves various important biological regulatory functions. For instance, in cyanide-producing bacteria (e.g., *Pseudomonas aeruginosa*), cyanide is known to play a role in quorum sensing and may act as a virulence factor and a mediator of biotic interactions [1–5].

In various plants, endogenously produced cyanide has been implicated in seed germination, plant development and in plant immunity [6–10].

In bacteria, cyanide is produced from glycine in an oxidative reaction catalyzed by the enzyme cyanide synthase, also known as glycine dehydrogenase (cyanide-forming). In plants, cyanide production is part of the camalexin or ethylene biosynthetic pathways. In one reaction, the cysteine-indole-3-acetonitrile

conjugate acts as the substrate for CYP71B15(PAD3) to produce hydrogen cyanide and dihydrocamalexic acid (in a subsequent step, the latter product is converted to camalexin). In another reaction that occurs in many plant species, 1-aminocyclopropane-1-carboxylic acid (ACC) acts as the substrate of ACC oxidase, with the products being ethylene, carbon dioxide, and hydrogen cyanide.

In contrast to bacteria and plants, for mammalian cells, cyanide is usually viewed as an environmental toxin and a poison. (In fact, the Swedish chemist Carl Wilhelm Scheele, who first isolated hydrogen cyanide, has reportedly died from the adverse health effects of cyanide poisoning in 1786). The environmental toxicology of cyanide has an extensive literature, focusing on industrial, environmental and alimentary sources, exposure levels, absorption, organ distribution, elimination and on the various therapeutic options (antidotes). These topics are the subject of specialized reviews [11–15]. Environmental sources of cyanide include various industrial processes, smoking and fires, intentional poisoning, and certain natural, alimentary sources of cyanides (over 2000 plant species, including cassava and many fruits and vegetables containing cyanogenic glycosides, almonds, and apricot kernels). There is also a significant iatrogenic source of cyanide: sodium nitroprusside.

Cyanide is especially toxic to cells and organs with high metabolic requirements. Accordingly, the primary targets of cyanide toxicity in mammals are the cardiovascular system and the central nervous system. Acute cyanide intoxication induces respiratory arrest, unconsciousness, convulsions, tremor, and ultimately death. The long-term exposure to nonlethal doses of cyanide is known to affect, among others, the endocrine system; it can also induce neurological defects and developmental/birth defects. In humans, the acute oral lethal dose of KCN is approximately 200 mg. In the gaseous form, the Immediately Dangerous to Life or Health value for inhaled hydrogen cyanide is 50 p.p.m. [11–15].

Hydrogen cyanide is a gas, but cyanide is also highly soluble in water and in biological fluids. Cyanide is a weak acid (pKa = 9.2). At physiological pH, approximately 98% of cyanide exists in the volatile undissociated form (HCN). The small size of this molecule, coupled with its solubility properties, allows it to rapidly cross-mucous membranes, ensuring a rapid uptake, followed by broad tissue distribution and action [11–15].

The vast majority of biomedical literature focuses on cyanide's cellular actions in an environmental toxicological context [11–15]. The cytotoxic effects of cyanide are primarily attributed to the inhibition of mitochondrial respiration, with cytochrome c oxidase (mitochondrial Complex IV) being cyanide's principal target. The first part of the current article focuses on the various cytotoxic mechanisms of cyanide, in the environmental toxicology context, and also details the small body of evidence implicating the action of bacterial cyanide in a pathophysiological context. The second part of the review focuses on a new direction in cyanide research, which—in stark contrast to the environmental toxicological aspects of cyanide—implicates cyanide as an endogenous mammalian product, which, at low concentrations, serves biological regulatory roles. Overview of these recently emerging data leads to the conclusion that cyanide may be an endogenous, biological mammalian gaseous mediator, belonging to the class of gasotransmitters (a group of mediators which also includes nitric oxide [NO], carbon monoxide [CO], and hydrogen sulfide [H_2S]).

Cyanide, as an inhibitor of mitochondrial respiration and as a cytotoxic agent

The discovery of the cellular respiration and cytochrome 'connection' and the delineation of the effect of cyanide on these responses is the result of the work of many scientists since the 18th century. The Italian biologist Lazzaro Spallanzani was the first to develop the hypothesis that lung respiration is associated with tissue respiration, a concept that remains one of the milestones of modern physiology [16]. Early studies on the inhibition of cellular respiration with cyanide were performed at the beginning of the 20th century by Battelli and Stern, who, studying oxidative reactions in animal tissue extracts in the presence of oxygen, observed that this process was inhibited by cyanide. Particularly, the experiments consisted of following the catalytic conversion of 'Nadi' reagent (a mixture of 1-naphthol and N,N-dimethyl-p-phenylenediamine) into indophenol blue, and the enzyme responsible for this reaction was called indophenol oxidase [17]. Some years later, the pioneering investigations of Warburg led to postulate the respiration theory, according to which, during cellular respiration, molecular oxygen is complexed with a catalytic iron compound called 'respiratory enzyme' (*Atmungsfermentum*) [18]. This theory was supported by the observation that cell respiration was inhibited by substances known to interfere with iron-catalyzed reactions, such as cyanide and CO. In a follow-up study, Warburg and co-workers, taking advantage of the photolabile bond between CO and ferrous heme, concluded that the iron of the

'respiratory enzyme' was complexed with a heme prosthetic group [19]. In 1929, Keilin identified this 'respiratory enzyme' as indophenol oxidase, later called cytochrome c oxidase (CCOx) [20]. Keilin showed that the activity of this enzyme was coupled with tissue respiration and, importantly, its activity was fully inhibited by low concentrations of cyanide [20]. In 1939, Keilin and Hartree showed that CCOx consisted of two cytochromes referred as a and a_3 and that cytochrome a_3 was able to combine with cyanide and CO [21]. The role of cyanide in the inhibition of CCOx was subsequently validated in *in vivo* studies, in which rats subjected to intraperitoneal injection of cyanide showed a significant decrease of CCOx activity in the brain. Treatment of cyanide correlated with an anoxic state, resulting in a shift from aerobic to anaerobic metabolism, thus supporting a model in which cyanide inactivates CCOx by interfering with the utilization of molecular oxygen [22].

In mammals, CCOx (EC1.9.3.1) is an enzymatic complex made of 13 different subunits. Among them, the subunits I (57 kDa), II ($\sim$ 25 kDa), and III (30 kDa) are involved in proton pumping activity responsible for the generation of the mitochondrial membrane potential ($\Delta\Psi_m$) [23,24]. The role of the other subunits has long been considered uncertain although is now recognized that some of them play an important role in modulating CCOx's activity. For instance, when the intramitochondrial ATP/ADP ratios are high, the energetic requirement lowers with a concomitant downregulation of the electron transport chain (ETC) activity. Interestingly, it has been shown that the subunit IV of CCOx displays a binding site for ATP and the interaction with this effector induces an allosteric inhibition of the enzymatic activity [25]. Moreover, as reviewed by Hüttemann and colleagues, CCOx contains phosphorylation sites in its different subunits (I, II, IV, Va). This post-translational modification induces a partial inhibition of CCOx and is important for maintaining $\Delta\Psi_m$ at 'healthy' levels (around 120 mV), which are sufficient for ATP synthesis [26]. Dysregulation of the CCOx phosphorylation (hypo- or hyperphosphorylation) has been associated with bioenergetic deficits. For instance, TNF-α-mediated acute inflammation is accompanied by phosphorylation on Tyr304 of subunit I of CCOx, resulting in full inhibition of its enzymatic activity, eventually leading to drop of $\Delta\Psi_m$ and ATP depletion. Conversely, dephosphorylation of CCOx leads to an increase of $\Delta\Psi_m$ over 150 mV and may lead to ROS generation and oxidative stress, a condition typically observed during ischemia/reperfusion [26]. Similarly, S-glutathionylation, a post-translational modification

involved in modulation of energy metabolism and oxidative damage prevention, has been observed in different mitochondrial complexes, including CCOx [27,28]. As shown working on HepG2 cells and isolated enzyme from bovine heart, we have reported that S-glutathionylation induces a downregulation of CCOx activity, and interestingly, this post-translational modification could be reversed by nanomolar concentrations of cyanide [29]. As discussed below, CCOx is also targeted by NO which is responsible for partial inhibition of its enzymatic activity and maintaining $\Delta\Psi_m$ levels under control [30].

For biochemical and biophysical studies, CCOx is typically obtained from beef heart and exists in homodimeric form. The single monomeric functional unit harbors 4 redox centers consisting of a bimetallic Cu_A, heme a, and the O_2-binding catalytic site made of heme a_3 coupled with Cu_B (Fig. 1) [23]. The first electron acceptor is Cu_A is localized in subunit II and is exposed to mitochondrial intermembrane space, where it interacts with the electron donor cytochrome c, thus undergoing one-electron reduction. Subsequently, reduced Cu_A donates the electron to heme a, thus triggering a structural transition involved in proton pumping [31]. Eventually, electrons are transferred from heme a to the heme a_3/Cu_B binuclear redox center. The latter is located in subunit I and represents the catalytical site where the reduction of oxygen takes place [32]. A_3/Cu_B is also targeted by a range of small molecules that are known to inhibit CCOx activity, namely, cyanide, H_2S, CO, and NO [26].

Mechanistically, the first evidence of the binding of cyanide to CCOx was reported by Keilin, who showed that cyanide binds to the heme a_3, both in the oxidized (a_3^{3+}) and reduced (a_3^{2+}) state. Particularly, the complex with the a_3^{3+} seems to be more stable than the one with a_3^{2+}, since the latter state is prone to auto-oxidation [21]. However, the interaction between a_3^{3+} and cyanide has been reported to be too slow to have any physiological relevance, thus suggesting that the a_3^{2+} state of the enzyme is the actual binding form [33]. A subsequent study comparing the binding parameters of cyanide to different states of CCOx, estimated that the partially reduced enzyme, populated during turnover, displays a binding affinity to cyanide that is 5 orders of magnitude higher as compared to the fully oxidized enzyme [34]. As shown by sequential mixing and rapid scan stopped flow spectroscopy, a one-electron reduction of a_3/Cu_B is sufficient to induce a rapid cyanide binding [29]. According to this model, the very first binding site is Cu_B and two possible mechanisms are conceivable. A single electron transfer from Cu_A/cytochrome a to a_3/Cu_B (a) induces a

Fig. 1. Cyanide as a Complex IV inhibitor and mitochondrial poison. CCOx dimer bounded to CN⁻. CCOx is localized in the mitochondrial inner membrane with the cytochrome c binding site exposed to the intermembrane space. The redox centers, namely, Cu_A, heme a, and the binuclear center heme a_3/Cu_B of a single monomeric unit are represented in different colors. In the reduced state, Cu_B is coordinated by His290, His291, His240, and Y244, and upon binding of cyanide, His290 is displaced, thus allowing the accommodation of cyanide between Cu_B and heme a_3. From the Protein Data Bank coordinates of the fully reduced bovine heart CCOx in the presence and absence of cyanide (PDB Id: 3AG1 and 3AG4), deposited by Muramoto and colleagues [30,36].

structural transition in the binuclear a_3/Cu_B center or, (b) reduces Cu_B, which is the site with the highest redox potential, from Cu^{2+} to Cu^{1+}. Both mechanisms lead to the dissociation of Cu_B from a bound intrinsic ligand (possibly His290), thus allowing the binding to cyanide [35,36]. Cyanide toxicity is generally considered to be due to an irreversible inhibition of the binding of molecular oxygen to the binuclear site a_3/Cu_B, although some reports showed that cyanide-induced inactivation of CCOx can, in fact, be also reversible. Intriguingly, Pearce *et al*. reported that cyanide inhibition of CCOx can be partially reverted by NO, another CCOx inhibitor ($\sim 10^3$-fold more effective than cyanide, as shown in Table 1) [34,37–39]. Importantly, NO proved to displace cyanide and, when the enzyme was in turnover, NO is gradually degraded (oxidized) in solution [39,40]. Moreover, as shown in freshly isolated rat liver mitochondria or hepatocytes, the inhibition of oxygen consumption and ATP synthesis after 10-min incubation with 250 μM of KCN was fully reversed by extensive washing in the incubation medium [41,42]. The reversibility of the cyanide inhibition of CCOx may open the possibility that

cyanide, similarly to NO, plays a physiological role in the modulation the cell respiration.

Since oxidative phosphorylation is essential for ATP generation in mammalian cells, a cyanide-mediated shutdown of Complex IV activity, and a consequent inhibition of mitochondrial electron transport and aerobic ATP generation would be expected to severely affect the function of all cells, especially those with high bioenergetic demand (e.g., developing/proliferating cells, neurons, cardiac myocytes). Indeed, *in vivo* or *ex vivo* studies show that ATP and high-energy phosphate content of the tissues decrease rapidly and precipitously after systemic exposure to cyanide [43–49] and the inhibition of mitochondrial Complex IV is well detectable in various tissues *ex vivo* [22,48,50–52]. In line with the inhibition of mitochondrial function, tissues exposed to cyanide lose their ability to extract oxygen, even in the presence of adequate blood flow [53,54], a phenomenon called 'cytotoxic hypoxia'. Nevertheless, in tissues with high levels of phosphocreatine pools (e.g., heart and skeletal muscle), the energetic deficit manifests itself in phosphocreatine depletion, rather than ATP depletion; the decrease of mitochondrial ATP generation may be

Table 1. Reaction characteristics of NO, CO, H$_2$S and HCN with cytochrome c oxidase

Inhibitor	Enzyme form	K_{on} (M^{-1} s^{-1})	K_{off} (s^{-1})	K_{off}/K_{on}	References
NO	Reduced	1.5×10^8	4×10^{-3}	0.03 nM	[23]
CO	Reduced	8×10^4	0.023	0.29 μM	[37]
H$_2$S	Reduced	1.5×10^4	6×10^{-4}	0.04 μM	[38]
HCN	Reduced, in turnover	2×10^6	4.7×10^{-2}	0.02 μM	[34]

temporarily compensated by a backward flux of creatine kinase [44,46,49,55].

Similarly to the *in vivo* findings, a large number of *in vitro* studies demonstrate that cyanide (typically applied in the concentration range of 100 μM–3 mM) produces a significant decrease in cell viability and/or cell proliferation, and these effects are usually linked to inhibition of cytochrome c oxidase activity and a rapid decrease in intracellular ATP content [42,56–63].

However, in addition to the effects of cyanide on mitochondrial Complex IV—a variety of additional, deleterious effects of cyanide have been reported in various *in vitro* experimental systems. For example, cyanide (at the relatively low concentration of 50–100 μM) was shown to enhance NMDA receptor activation and the consequent calcium mobilization response [64,65]. Cyanide, at millimolar concentrations, was reported to exert selective effects on NMDA receptor subtypes: It potentiates the activation of NR1/NR2A receptors, most likely via the chemical reduction of NR2A, but it does not potentiate the activation NR1/NR2B receptors (rather, it exerts a slight inhibitory effect) [66,67]. Exposure of various cell types to cyanide was also found to produce an intracellular Ca^{2+} response, which, at low cyanide concentrations (starting at 1 μM) produces a stimulation of intracellular inositol triphosphate level, followed by Ca^{2+} mobilization from intracellular calcium pools [64]. At higher cyanide concentration, (starting at 100 μM and becoming pronounced at 300 μM–1 mM) Ca^{2+} mobilization in various neuronal cell types was also shown to involve the influx of extracellular calcium through L-type membrane calcium channels and NMDA receptors as well as further intracellular Ca^{2+}-release from the endoplasmic reticulum and mitochondria [65,68–75] as well as an inhibition of active Ca^{2+} extrusion from the cells [70]. Increased intracellular Ca^{2+}, in turn, increases the activity of Ca^{2+}-dependent enzymes (e.g., phospholipase A2, caspases, proteases, and endonucleases) [76–81]. Cyanide (in millimolar concentrations) induces nuclear and mitochondrial DNA fragmentation [82,83]; it can also cause microtubular disruption [84]. Cyanide treatment of various cell types

has also been shown to suppress K$_{ATP}$ channel and inwardly rectifying K$^+$ channel activity [85,86]. Activation of NF-κB after cyanide exposure [87,88] may link cyanide's cellular effects to changes in signal transduction, gene expression and/or to regulated pathways of cell death (apoptosis).

In neurons, the apoptotic form of cyanide-induced cell death—which typically occurs at approximately 100–300 μM cyanide—appears to be more related to calcium overload, BNIP3 mobilization, cytochrome c release, and caspase activation, while the necrotic form of cell death (which typically occurs at cyanide concentrations higher than 300 μM) is linked to mitochondrial inhibition of ATP generation, mitochondrial dysfunction (which also involves upregulation of uncoupling protein 2 in the mitochondria), activation of poly (ADP-ribose) polymerase (PARP), and overall cellular bioenergetic deficit [89–91]. In the brain, cyanide was also demonstrated to cause a rapid-onset increase in lipid peroxidation [92–94]. High concentrations of cyanide (1–10 mM) cause a significant intracellular acidification as well [95]. Cyanide, via activating the above-listed pathophysiological pathways, can induce the release of various neurotransmitters (e.g., glutamate and dopamine) from the damaged cells [92,96]. At extremely high concentrations, cyanide can also exacerbate the neurotoxic effect of various mediators, for example, NMDA and dopamine [97–101]. These actions may contribute to cyanide-associated CNS injury *in vivo*.

Some of the effects of cyanide listed in the previous paragraph may be secondary to inhibition of Complex IV. For instance, when inhibition of mitochondrial electron transport occurs, the percentage of oxygen incompletely reduced by mitochondria will be increased, leading to oxygen free radical (ROS) formation due to the dysfunctional operation of the electron transport chain [89,99,100,102,103]. ROS, in turn, can promote the activation of NF-κB after cyanide exposure [87]. ROS may also induce the release of calcium from the mitochondria, which, in turn, may activate various intracellular enzymes that mediate DNA fragmentation or apoptosis [82,104–106]. Microtubular

assembly and movement is also a highly ATP-dependent process, and its disruption would be expected if mitochondrial ATP generation is impaired. The effects of cyanide on various potassium channels may also be —partially or completely—the consequence of intracellular ATP suppression, via processes that have been proposed to involve, in some cases, modulation of phosphatase activity [85,86]. However, some of the other reported cellular effects of cyanide are probably independent of Complex IV inhibition (or ATP depletion or ROS generation). For example, the stimulatory action of cyanide on NMDA receptors is independent of mitochondrial or bioenergetic actions (see below). Some of the key pathways of cyanide cytotoxicity, leading either to apoptotic, or necrotic cell death, are shown in Fig. 2.

There are several lines of studies that are inconsistent with the 'central dogma' that cyanide causes an irreversible inhibition of Complex IV activity, followed by the loss of ATP, and this effect is directly responsible for the impairment of cell viability and function. For instance, in hepatocytes, the cyanide (250 μM–1 mM, 10 min) induced a depletion of cellular ATP pools, ATP levels rapidly and completely recovered after washout of cyanide from the medium [42]; this response pattern is not consistent with an irreversible inhibition of ATP biosynthesis. A similar reversibility of the cyanide-induced suppression of ATP was also noted earlier in a perfused liver preparation [107]. It is possible that, in the presence of a sufficient concentration of reducing equivalents, cyanide may be physiologically dissociated from the CCOx/inhibitor complex: that is, inhibition of CCOx by cyanide, at least under certain conditions and in certain cell types, can be reactivatable. (A similar type of reactivation, using various pharmacological approaches, is one of the principles of cyanide antidotes [108]). Moreover, as noted above, cyanide already at relatively low concentrations (e.g., 50 μM) enhances NMDA receptor activation. This response has been demonstrated in


Fig. 2. Pathways contributing to the cytotoxic actions of cyanide in mammalian cells. (A) Typically, at high micromolar concentrations (e.g., 100–300 μM in neurons), cyanide induces apoptotic cell death. Early stages of this process include mobilization of calcium from intra- and extracellular pools. This calcium mobilization (possibly, in combination with a partial inhibition of CCOx and mitochondrial dysfunction, coupled with ER dysfunction), stimulates various effectors of apoptotic cell death. For instance, ROS are generated either by cyclooxygenase (which is stimulated by calcium mobilization) or by the mitochondria (as a consequence of CCOx inhibition). ROS and calcium stimulate various apoptotic effectors (e.g., endonucleases, caspases), BNIP3 (BCL2 and adenovirus E1B 19-kDa-interacting protein 3) and signaling pathways (e.g., NF-κB). These processes culminate in apoptotic cell death; these cells are typically eliminated by phagocytes and do not exacerbate local inflammatory responses. (B) Typically, at low millimolar concentrations (e.g., 1–3 mM), cyanide induces necrotic cell death. A central part of this process is a pronounced inhibition of CCOx and mitochondrial dysfunction, also reflected in severe degree of cellular ATP depletion. An additional factor in this process is calcium overload, followed by activation of PKC. Mitochondrially derived ROS (perhaps together with ROS formed by other cellular sources and perhaps also in combination with NO to form peroxynitrite) induces DNA single strand breakage, which is a direct activator of the nuclear enzyme PARP. PKC activation, and PARP activation, further depletes cellular NAD^+ and ATP levels. Because of the low cellular ATP, cells are unable to maintain the activity of membrane pumps and the membrane potential dissipates and the cell starts to 'leak' and release its intracellular content. During full-fledged necrosis, all cellular content is released as the cell disintegrates. This process can, in turn, lead to additional local or remote inflammation.

reductionist preparations that don't contain mitochondria (e.g., measurement of single channel activity in excised outside-out membrane patches) and therefore must be the consequence of direct effects of cyanide on these receptors, possibly via a direct action on redox sensitive disulfide groups [66,67]. At higher concentrations [1 mM], cyanide may also, at least in part, act in a direct fashion on the NMDA receptor, by interacting with its Mg^{2+} block [98]. Sun and Reis have reported that cyanide (30–300 μM) activated Ca^{2+} currents in pacemaker neurons of rat rostral ventrolateral medulla *in vitro* in the absence of significant cellular damage [109]. A similar, ATP-independent suppression of myocardial contractility has also been reported [110]. Moreover, in a guinea pig hippocampal preparation, cyanide, at the relatively low concentration range of 10 μM–200 μM, decreased synaptic transmission; the effects were rapidly reversible by washout and therefore are unlikely to be related to an irreversible inhibition of Complex IV [111]. In a rat diaphragm preparation, cyanide (100 μM–1 mM), unexpectedly, produced an initial increase (rather than decrease) of muscle contractility, followed by a decrease at later time points; neither the increase nor the decrease in contractility was associated with any detectable change in the ATP content of the muscle (although the decline of contractility was associated with decreased phosphocreatine levels); moreover, contractile function returned to normal after washout of cyanide from the preparation [112]. The effect of cyanide was suggested to be related to an action of the contractile apparatus, perhaps an ability of cyanide to influence the sensitivity of the contractile proteins to Ca^{2+} [112].

A separate class of cyanide's cellular actions relates to the activation of protein kinase C (including the PKCε isoform), with a variety of signaling and/or deleterious responses (including the phosphorylation of α1c subunit of L-type Ca^{2+} channel and the α2 subunit of Na^+-K^+-ATPase). These effects can be relevant in the context of cyanide toxicity, but they do not appear to be associated with a detectable decrease in total cellular ATP levels [113]. Importantly, the observation that PKC inhibition can attenuate the cyanide-induced cell necrosis *in vitro* and *in vivo* [49,114] indicates that the PKC-dependent effects may be independent from the mitochondrial/bioenergetic responses induced by cyanide; in neuronal tissue they may be, however, the consequences of NMDA receptor activation [115].

It should be mentioned that cyanide is a direct inhibitor of several enzymes in addition to cytochrome c oxidase. These include succinic acid dehydrogenase, superoxide dismutase, carbonic anhydrase, glutathione peroxidase, NADPH oxidase, myeloperoxidase, glutamic acid decarboxylase, and gamma-aminobutyric acid transaminase [115–120]. In contrast, monoamine oxidase A (but not monoamine oxidase B) activity was reported to increase in response to cyanide [121]. The effect of cyanide on NADPH oxidase is variable; inhibition, activation, or no effect were all reported under various experimental conditions [122–125]. The potential contribution of cyanide's action on these enzymes is incompletely understood but is most likely only relevant in the toxicological context. In Syrian hamster embryo cells, the cyanide (500 μM) induced DNA fragmentation and cytotoxicity appears to be a combined result of mitochondrial inhibition, mitochondrial ROS release as well as a parallel, independent inhibition of catalase and superoxide dismutase [126].

It should be emphasized that *in vitro*, the effect of cyanide on mitochondrial function and cell viability can be variable, depending on the cell type, the characteristics of the culture medium used (glucose, CO_2, pH), as well as different physicochemical factors (e.g., the degree of loss of cyanide gas from the culture medium due to outgassing) [63,127]. Also, cells in culture can be highly glycolytic. Thus, the cyanide-induced shutdown of aerobic ATP generation may be partially compensated by ATP generation from glycolysis [22,128–133]. In fact, in many experiments, complete inhibition of cellular ATP synthesis can be only achieved when the cyanide-mediated inhibition of oxidative phosphorylation is combined with pharmacological inhibitors of glycolysis [29,129,134,135]. However, cellular ATP generation after cyanide exposure can also be influenced by the fact that cyanide may also have direct inhibitory effect on glycolysis: in hepatocyte intermediary metabolism, cyanide was reported to decrease glucose catabolism by inhibiting the glycolytic pathway (while also producing a shunt, with a resulting increase in glucose catabolism by the pentose phosphate pathway) [136].

Bacterial cyanide can exert pathophysiological effects to mammalian cells

In the previous sections, the mammalian cell was viewed as a target of environmental cyanide exposure. There are, however, some pathophysiological conditions where bacterially generated cyanide has been implicated as a pathophysiological (cytotoxic) factor to mammalian cells. The best studied example is cystic fibrosis (CF), a progressive genetic disease, in which the colonization of the lung with *Pseudomonas aeruginosa* (an opportunistic pathogen) is a common occurrence and a significant pathogenetic factor [137–139].

As noted earlier, *Pseudomonas aeruginosa* is a cyanide-producing bacterium; cyanide concentrations in the supernatant of these bacteria can reach several hundred micromolar levels [140–142]. It appears that this bacterially produced cyanide can exert deleterious effects on the host lung. Indeed, cyanide levels as high as several hundreds of µM have been detected in the sputum of CF patients with *Pseudomonas aeruginosa* lung infection [142–144]; secondary species such as cyanogen chloride (CNCl) and the carbamoylating species cyanate (OCN⁻) were also detected [145]. HCN gas has also been detected in the exhaled breath of these patients; in fact, exhaled HCN has been proposed as a potential diagnostic biomarker of *Pseudomonas* colonization of the lung [146–151].

Pseudomonas-derived cyanide serves as a bacterial 'weapon' to suppress the growth of competing, co-colonizing bacteria (e.g., *Staphylococci* or *Burkholderia cenocepacia*) in the lung [152,153]. Moreover, *Pseudomonas*-derived cyanide can have deleterious effects on the host airway. As discussed in the previous section, cyanide concentrations of 100 µM and higher are significantly cytostatic or cytotoxic to mammalian cells. Therefore, it is likely, that the pulmonary epithelial cells, which are exposed to the highest local concentrations of cyanide, will be adversely affected by cyanide. Indeed, exposure of human pulmonary epithelial cells (obtained from nasal brushings) to cyanide (75–150 µM) produced a significant decrease in ciliary beat frequency, which may predict that *Pseudomonas* in CF lungs may impair the ability of the epithelial cell to perform effective mucociliary clearance [154]. Moreover, bacterial supernatant transfer studies demonstrate that concentrated supernatants of *Pseudomonas aeruginosa* can suppress mitochondrial respiration via inhibition of Complex IV activity in mammalian cells; this suppression is no longer noted after the deletion of the cyanide-producing enzyme in the bacteria [29]. As discussed by Anderson [143], bacterial cyanide may also have additional adverse effects on the host beyond inhibiting mitochondrial function and viability of epithelial cells, such as immunosuppressive effects and/or interference with the function of neutrophil granulocytes. Taken together, bacterial cyanide may well be a significant contributor to the pathogenesis of cystic fibrosis-associated pulmonary dysfunction. Importantly, Ryall *et al.* demonstrated that sputum cyanide shows a negative correlation with lung function in CF patients [155], perhaps indicating that cyanide contributes to lung dysfunction in CF (although this may also be related to the fact that patients with more severe *Pseudomonas* colonization tend to have a more advanced lung disease, in

general). To our knowledge, so far there have not been any experimental or clinical studies performed attempting to scavenge or neutralize or inactivate the cyanide-producing gene in *Pseudomonas* in the context of experimental CF therapy. There are several classes of cyanide scavengers/antidotes, and some of these agents—for example, vitamin B12a—tend to have a fairly excellent safety profile and are already used in clinical trials, for instance in the context of burn-associated cyanide poisoning [156]. Also, inhaled NO has been proposed to interfere with the cyanide-producing ability of *Pseudomonas* [157]. Approaches exploiting these mechanisms may be the topics of potential future preclinical proof-of concept studies and possibly subsequent clinical trials.

There are many unexplored directions in the above line of research. For instance, the lung can also be colonized by cyanide-producing bacteria in other forms of pulmonary disease (e.g., noncystic fibrosis bronchiectasis and asthma) [138]. It should be also noted that endogenous (mammalian cell produced) cyanide may also be relevant factor in contributing to sputum or exhaled air cyanide levels [145,158]. Although the focus of most work related to bacterial cyanide production focuses on *Pseudomonas*, several other bacterial pathogens (e.g., *Burkholderia cenocepacia*) also produce cyanide. Some of these pathogens can colonize the lung in CF [159]; others may be pathogenetic factors in other lung diseases (e.g., 'cepacia syndrome' or necrotizing pneumonia) or in systemic infections and septic shock. Indeed, when various 'model organisms' are co-cultured with cyanide-producing *Pseudomonas* species, the model organisms exhibit signs of metabolic suppression and injury. For instance, co-culture of *C. elegans* with cyanide-producing *Pseudomonas* produces rapid paralysis and killing of the nematodes, with cyanide being the principal agent responsible for this action [160,161]. Similarly, cyanide-producing human *Pseudomonas* isolates are toxic, in a significant part due to cyanide production, to *Drosophila melanogaster* co-cultures [162]. *Pseudomonas* species are common pathogens in urinary tract infections; the potential role of the 'cyanide connection' in this context remains to be explored.

Population-based incidence studies indicate that only approximately 2–8% of all septic shock cases include systemic *Pseudomonas* bacteremia, but these cases tend to be associated with severe clinical picture and high mortality [163–167]. To our knowledge, circulating cyanide levels have not been assessed in these patients. It is conceivable that systemic cyanide may impair mitochondrial function in *Pseudomonas* bacteremia via the mechanisms discussed above. Based on various

vascular studies with cyanide [168–172], we believe it is also conceivable that circulating cyanide in *Pseudomonas* sepsis may also exert deleterious effects on the endothelial cells and vascular smooth muscle cells, impairing endothelial function and contributing to vascular contractility. Further work is required to investigate whether systemic *Pseudomonas* infection, and the consequent systemic cyanide exposure may contribute to the pathogenesis of cell and organ dysfunction.

Endogenous generation of cyanide in mammalian cells

As discussed in the Introduction section, many living organisms contain cyanide-producing enzymes; there are many strains of cyanide-generating bacteria, which produce cyanide for regulatory purposes or as a virulence factor; moreover, plant-generated cyanide mediates various processes, from plant growth to plant immunity. Although cyanide synthesis by mammalian cells has not been investigated extensively, several studies indicate that mammals have detectable circulating cyanide concentrations, and cyanide production has been demonstrated in various mammalian cells and tissues. Utilizing a variety of methods the basal circulating cyanide concentration in healthy volunteers has been estimated to be in the range of 1–5 μM [173–177]. Perhaps these methods overestimate the concentration of cyanide, at least in part because some of these methods may also include thiocyanide. Using a capillary gas chromatography method, basal cyanide concentrations in healthy humans were found to be lower: approximately 300 nM [178]. The cyanide metabolite 2-aminothiazoline-4-carboxylic acid (ATCA) is also detectable in significant levels in the blood and tissues of humans or experimental animals without any prior exposure to exogenous source of cyanide [175,179,180]; another cyanide reaction product (protein-bound thiocyanate) was also detected (in approx. 600 nM concentration) in the blood of healthy individuals [181]. Cyanide levels in the exhaled breath of healthy human beings have been quantified to be in the 4–62 ppb range [173,182–184], with significant increases in patients with *Pseudomonas* colonization in their lungs (see above). Circulating cyanide levels are increased 3- to 4-fold in smokers; they are markedly increased in various exogenous cyanide exposure situations (for instance, blood cyanide levels increasing to approximately 25–100 μM in fire victims) [175,178,185]. Interestingly, circulating cyanide and cyanide metabolites also exhibit significant increases in hemodialysis patients, most likely due to impairment of various cyanide detoxification and elimination pathways [186–188].

Through the use of enzyme repositories systems, such as BRENDA (https://www.brenda-enzymes.org/), we were able to find at least 14 different enzymes producing cyanide, but not all of them are relevant for the scope of the present review. Indeed, many of them are expressed in plants as part of chemical defense system adopted in case of peril, represented by pathogens or herbivores. For instance, many plants biosynthesize cyanogenic compounds, such as cyanohydrins, to be used as substrates for the rapid production of cyanide [189]. At least 5 cyanide-producing enzymes have been identified in mammals. Within this subgroup, a distinction must be made between enzymes producing cyanide from *endogenous* substrates vs. those producing cyanide from xenobiotics. Indeed, while the former class of enzymes are potentially capable of releasing cyanide constantly (to yield cyanide in low and non-toxic concentrations), the latter class of enzymes release cyanide only in certain circumstances, such as upon exposure to cyanogenic compounds derived from the diet (fruit and vegetables) or after exposure to drugs or pesticides.

From currently known list of mammalian enzymes producing cyanide from endogenous substrates, myeloperoxidase (MPO) [EC1.11.2.2] is potentially the most significant one. MPO is a heme-containing enzyme, encoded in humans by the *MPO* gene (NCBI gene ID: 4353) located on chromosome 17. MPO is abundantly expressed in neutrophils and monocytes (but also present in many other cell types), and it is believed to play an important role in the innate immune system [190]. This enzyme has been shown to display a substrate promiscuity, being able to catalyze a number of side reactions [191], including the generation of cyanide from glycine [192,193]. From the mechanistic point of view, MPO is involved in the process responsible for the protection against microbes' infections by releasing toxic agents, such as ROS [194]. The most widely recognized activity of MPO is the oxidation of chloride, bromide, or thiocyanate to the strongly oxidizing agents, HOCl, HOBr, and HOSCN, respectively. For these reactions, the enzyme uses hydrogen peroxide (H_2O_2) (released from superoxide dismutase). These activities are controlled by environmental factors, such as substrates availability and pH. For instance, although thiocyanate has a higher affinity for MPO with respect to the other substrates, the reaction with chloride is often favored because of the higher abundance of this anion in the cellular milieu [191]. The pH also plays a crucial role, as it influences the affinity of both H_2O_2 and Cl^- for MPO. Particularly, H_2O_2-dependent reactions occur preferentially at pH values around 6, while the K_M of Cl^-

has been shown to be optimal at lower pH. As a consequence, depending on the pH, other ligand may compete with the 'canonical' substrates for the enzymatic active site. This has been reported, for instance, for glycine, which at low pH undergoes catalytic chlorination by MPO to generate N-monochloro-glycine intermediate, followed by nonenzymatic release of cyanide [192]. Conversely, at higher pH values, cyanide has been reported to be chlorinated to cyanogen chloride (ClCN) by MPO, thus suggesting a dual role for cyanide, being both a substrate and a product of MPO [192,193].

Another mammalian enzyme capable of cyanide generation is cyanocobalamin reductase [EC1.16.1.6], also known as CblC or MMACHC [195]. This enzyme is generally known for its role in the metabolism of vitamin B_{12}. Vitamin B_{12} is commonly used in multivitamin formulations in the form of cyanocobalamin (CNCbl), which is converted in the body to its active form methylcobalamin (MeCbl) and 5'-deoxyadenosylcobalamin (AdoCbl) [195]. This reaction consists of a reduction CNCbl, in the presence of reducing equivalents provided by NADPH and $FADH_2$, leading eventually to the reduction of Co^{+3} to Co^{+2} and the concomitant release of cyanide [195]. In humans, cyanocobalamin reductase is encoded by the *MMACHC* gene (methylmalonic aciduria and homocystinuria type C protein), located in chromosome 1 (NCBI gene ID: 25974). Mutations of this enzyme have been associated with methylmalonic acidemia, an inborn metabolic disorder leading to neuronal damage [196,197].

Another cyanide-producing mammalian protein has been reported to be hemoglobin, which catalyzes the peroxidation of thiocyanide thus generating cyanide and sulfate as final products [198]. This reaction has been shown to occur only in the erythrocytes, where the enzymes catabolizing cyanide are absent. The physiological relevance of this reaction has been shown both *in vitro* and *in vivo* systems, thus suggesting the existence of a metabolic equilibrium between thiocyanate and cyanide [198,199].

Among the additional, currently known, mammalian cyanide-producing enzymes, many are microsomal enzymes involved in the metabolism of cyanogenic xenobiotics. For instance, carboxylic esterase has been shown to catalyze the hydrolysis of pyrethroids, a class of insecticides, to the correspondent cyanohydrin, followed by nonenzymatic hydrolysis to an aldehyde with the elimination of cyanide [200]. Aliphatic nitriles, another class of cyanogenic compounds widely employed in the production of vitamins and pharmaceuticals, are mainly metabolized by the CYP2E1/

epoxide hydrolase system. Particularly, these compounds undergo epoxidation by cytochrome CYP2E1, followed by hydrolysis catalyzed by epoxide hydrolase, a reaction considered crucial for the liberation of cyanide [201]. It is conceivable that the CYP2E1/epoxide hydrolase system may also have endogenous mammalian substrates, but this possibility has not yet been seriously explored in the literature. Similarly, the system α-hydroxynitrile glucoside/β-glucosidase has been suggested to be a 'cyanide bomb' in plants [202]. Although β-glucosidase is widely expressed in mammalians, cyanide release is unlikely to occur because of the absence hydroxynitrile glucoside, mostly represented in the plant kingdom. The key mammalian endogenous cyanide-producing pathways, and, for comparison, some of the most common cyanide-producing pathways in plants and bacteria are shown in Fig. 3.

In vitro studies have also demonstrated the ability of mammalian cells and tissues to produce significant amounts of cyanide, at least in part, in a regulated fashion. Indeed, since the early 1980s, it has been established that phagocytizing neutrophils can produce cyanide, in part by utilizing endogenous and in part by utilizing bacterial substrates [145,193,203–207]. Moreover, the ability of MPO to generate cyanide has also been demonstrated using the purified MPO enzyme [193,208]. In a subsequent line of studies, Borowitz and colleagues have quantified basal cyanide generation from PC12 cells (a rat cerebellar granule cell line) as 5.5 ng·10^{-6} cells/10 min, with an approximately 3-fold increase in response to μ-opiate agonist stimulation; similar results were also obtained in primary rat cerebellar cells [209,210]. Muscarinic receptor stimulation, in contrast, decreased neuronal cyanide generation [211]. Glycine also increased cyanide production in PC12 cells [210]; the underlying mechanism may be related to the previously characterized pathway whereby N-chlorination of glycine can be catalyzed by MPO, followed by secondary reactions of N-chloramines of glycine, which yield cyanide (as well as cyanogen chloride) (see above). A pharmacological inhibitor of myeloperoxidase decreased opiate agonist-stimulated (but not basal) cyanide production [210]. The differential effect of this agent on basal and stimulated cyanide production may indicate different enzymatic sources for these two types of cyanide production, although this possibility remains to be further investigated.

Significant levels of cyanide were measured in rat and hamster brain microdialysates *in vivo*; in these systems, μ-opiate agonist stimulation increased cyanide levels by about 5-fold [209]. Borowitz and colleagues

Cyanide generating pathways in mammals

Cyanide generating pathways in other organisms

Fig. 3. Physiological cyanide-generating systems in mammals and other organisms. Solid arrows represent enzyme catalyzed reactions, while dashed arrows stand for nonenzymatic degradation. (A) MPO catalyzes the chlorination of glycine into N-dichloro-glycine, which is an unstable compound and decomposes to its corresponding nitrile, followed by nonenzymatic release of cyanide and carbon dioxide. (B) Cyanocobalamin reductase (MMACHC) catalyzes the decyanation of CNCbl to yield cob(II)alamin (Cbl) and cyanide. (C) Carboxyl esterase catalyzes cypermethrin (an insecticide of the family of pyrethroids) hydrolysis to its corresponding cyanohydrin. Cyanohydrins are unstable species which give cyanide as product of degradation. (D) Aliphatic nitriles undergo epoxidation catalyzed by the microsomal enzyme CYP2E1, followed by liberation of cyanide by epoxide hydrolyze (EPHX). (E) In plants β-glucosidase/hydroxynitrile lyase system is believed to be one of the main sources of free cyanide. Cyanogenic glucosides are processed by β-glucosidase thus producing the correspondent cyanohydrin, which are then converted to aldehyde (or ketone) by hydroxynitrile lyase, with the concomitant elimination of cyanide. (F) Ethylene in plants is considered a hormone involved in many processes. The ethylene synthesis is accomplished by the oxidation of 1-aminocyclopropane-1-carboxylic acid (ACC), by ACC oxidase, into ethylene and cyanoformic acid. The latter spontaneously decomposes in cyanide and carbon dioxide. (G) Cyanide production from glyoxylate has been observed in algae (*Chlorella vulgaris*), spinach (*Spinacia oleracea*), corn (*Zea mays*), and barley leaves. In the presence of hydroxylamine, glyoxylate generates glyoxylate oxime, followed by degradation into cyanide, carbon dioxide, and water. The enzyme catalyzing this reaction has a molecular mass of 40 kDa and has been established to require for its catalytic activity ADP and Mn^{2+}. (H) Camalexin is a characteristic alkaloid of *Arabidopsis thaliana* accumulated upon infection of a variety of pathogens. The final steps of its biosynthesis are controlled by CYP71B15, which catalyzes both the formation of thiazolidine ring of cysteine-indole-3-acetonitrile, with the concomitant release of cyanide, and the subsequent oxidative decarboxylation of dihydrocamalexic acid to camalexin. (I) Cyanide biosynthesis from aromatic amino acids (histidine, tyrosine, and phenylalanine) has been observed in the alga *Chlorella vulgaris* and in spinach leaves. The reaction has been shown to be catalyzed by amino acid oxidase co-incubated with Mn^{2+} and horseradish-peroxidase, thus causing the formation of cyanide. Several bacterial species (the most extensively characterized being *Pseudomonas aeruginosa*) are known to produce cyanide. The immediate precursor of cyanide is glycine which is converted to cyanide and carbon dioxide in a reaction catalyzed by hydrogen cyanide synthase.

estimated whole rat brain cyanide concentration of 0.14 $\mu g \cdot g^{-1}$ wet weight (i.e., approximately 7 μM), with the hippocampus and the hypothalamus being the highest cyanide-producing regions [209]. In a recent study, Long and colleagues used confocal imaging methods and a fluorescent cyanide probe in cultured

PC12 cells and measured low, but detectable levels of cyanide under baseline conditions; in line with prior findings of the Borowitz group, the cyanide signal increased with μ-opiate agonist to the cells; the concentrations of cyanide in these cells were estimated at 8 μM under baseline conditions and 23 μM after μ-

opiate agonist stimulation [212]. Low, but detectable basal cyanide signals were also detected in cultured neurons and the hepatoma line HepG2 [212].

Biological reactivity of cyanide in mammalian cells

Undoubtedly, the best characterized reactivity of cyanide in biological systems is its propensity to bind transition metals, such as Fe(II), Fe(III), or Co(III), where it forms low spin complexes, reflecting its strong-field ligand character. Indeed, its negative electric charge along with its capacity to form both σ- and π-bonds, allows to stabilize transition metals in different oxidation states [213]. Its reactivity toward a wide range of metals makes cyanide a potential inhibitor of many metalloproteins, thus displaying an effect which goes well beyond the mere inactivation of the oxidative phosphorylation, as previously discussed. Along with the aforementioned CCOx, the interaction of cyanide with other heme-proteins such as hemoglobin (and myoglobin) has been extensively studied since the beginning of the last century, as reviewed by Fanelli and colleagues [214]. According to their proposed model, two molecules of cyanide are complexed in one heme moiety, thus obtaining a mono- and a di-cyanide ferroprotoporphyrin IX, in a stepwise manner [214].

Another iron heme protein targeted by cyanide is MPO, whose catalytic iron is responsible for the interaction with nucleophilic substrates. As mentioned above, this enzyme both synthesizes and catabolizes cyanide; high cyanide concentrations have been reported to inhibit its enzymatic activity [119,215]. Iron-cyanide interactions has been reported also for nonheme iron proteins, such as transferrin and Fe-superoxide reductase (Fe-SOD) [216,217]. Interestingly, cyanide has been shown to inhibit also Zn, Cu-superoxide dismutase (Zn, Cu-SOD): as shown with NMR spectroscopy, cyanide binds to the catalytic copper of Zn, Cu-SOD thus preventing the interaction with the superoxide anion O_2^- [218]. This is in line with the observation that many copper-dependent enzymes are indeed sensitive to cyanide, including CCOx (as discussed earlier).

Moreover, cyanide has been reported to inhibit zinc-dependent enzymes such as alkaline phosphatase and carbonic anhydrase and this effect could be reversed by addition of Zn^{2+} ions, thus suggesting that cyanide inactivates the enzyme by removing of Zn^{2+} from the active site [219,220]. The interaction of cyanide with gold has been reported to have therapeutic applications. Indeed, aurothiomalate, a gold complex used for the treatment of rheumatoid arthritis, has been suggested to be a prodrug of aurocyanide, the actual mediator of its anti-rheumatic action, whose formation is promoted by MPO-derived cyanide [206,207]. A common cyanide antidote is cobalamin, in which a cobalt ion is complexed with a corrinoid ring. Cobalt (III), similarly to the iron heme, is able to bind both one and two molecules of cyanide, thus generating mono-cyano and di-cyano-cobalamin [221]. The effectiveness of cobalamin as cyanide antidote is due to the fact it is able to bind cyanide with a greater affinity ($K_A \sim 10^{12}$ M^{-1}) [221] as compared to heme-proteins, such as CCOx ($K_A \sim 10^7$ M^{-1}) [31].

Carbamylation is another, biologically relevant reaction catalyzed by cyanide in various cells and tissues. Carbamylation is a nonenzymatic post-translational modification caused by the irreversible reaction of isocyanic acid (HCNO) with protein free amino groups, such as α-NH_2 group of terminal residues or ε-NH_2 group of lysine residues, although the latter occurs with $\sim$ 100 times lower rate than the former [222]. This post-translational modification is associated with structural and functional alterations of target proteins such as tubulin, in which case it leads to the inhibition of microtubule assembly. Moreover, carbamylation has been associated with enzyme loss of function, as shown for superoxide dismutase, aspartate aminotransferase and matrix metalloproteinase-2. Importantly, protein carbamylation has been associated with molecular aging, as well as a variety of diseases including atherosclerosis, chronic kidney disease, and rheumatoid arthritis [222,223]. The biochemical pathways leading to formation of isocyanic acid are typically (a) spontaneous dissociation of urea into ammonia and cyanate [224] or (b) catalytic conversion of cyanide (or thiocyanate) to cyanate by MPO [225,226]. As discussed above, this enzyme is abundantly expressed in inflammatory cells, such as neutrophils and monocytes, and its role in isocyanic acid formation has been associated with lipoprotein carbamylation and atherosclerotic plaques formation [227].

Cyanide is a typical 'anthioanion', a term referring to anions with a such high affinity for sulfur atoms that they form a stable thioanion when they react with elemental sulfur [228]. Indeed, cyanide is a strong nucleophile which readily reacts with sulfur–sulfur atoms through nucleophilic displacement, thus producing thiocyanate [229]. Protein disulfides are also susceptible to nucleophilic displacement in the presence of cyanide, thus generating a nonenzymatical post-translational modification on protein cysteine residues called S-cyanylation [230]. Although for a long time the occurrence of this protein post-translational modification has been shown only *in vitro* using artificial

conditions [231,232], more recently it has been demonstrated that cyanide reacts with protein disulfide of human serum albumin and immunoglobulin G in a more physiologically relevant context [233].

As already mentioned in a previous section of our article, cyanide has been reported to target NMDA receptors by influencing the redox state of NR1/NR2A and NR1/NR2B channels, thus resulting in a modulation of their activity, yet with opposite effects. Indeed, while cyanide increased frequency and opening time of NR1/NR2A channels, it decreased opening frequency of NR1/NR2B channels. The latter modification is believed to be due to cleavage of the redox site [744]Cys-SS-Cys[798], leading to the formation of a thiocyanate adduct [65]. It is now well accepted that S-cyanylation occurs naturally in plants, and it is believed to play a role in the modulation of crucial metabolic pathways, such as energy metabolism (glycolysis and TCA cycle) and S-adenosyl methionine cycle. As shown in *Arabidopsis thaliana* roots extracts by employing two independent methodological approaches, such as liquid chromatography-tandem mass spectrometry and 2-iminothiazolidine chemical method, were identified 163 proteins susceptible to S-cyanylation [4]. Among these, glyceraldehyde-3-phosphate dehydrogenase and isocitrate dehydrogenase have a high percent homology ($\sim$ 70%) with human orthologs. Hence, it is conceivable that S-cyanylation occurs in mammalian cells and tissues; This possibility remains to be explored in the future.

S-glutathionylation is another post-translational modification of protein cysteine residues by addition of glutathione. This modification has been shown to occur in several enzymes involved in energy metabolism, including α-ketoglutarate dehydrogenase, isocitrate dehydrogenase, mitochondrial complexes I, II, and IV [27,28]. S-glutathionylation is often linked to oxidative stress (although it was identified in unstressed cells as well) by preventing irreversible oxidation of protein thiols along with modulating enzyme activity [27,234]. Recently, we have reported that the S-glutathionylated form of CCOx is less active as compared to its native form [29]. Interestingly, the de-glutathionylation of CCOx could be obtained in the presence of nanomolar concentrations of cyanide, as shown both in HepG2 cell line and isolated enzyme from bovine heart [29]. The cyanide-mediated de-glutathionylation was responsible for the increase of CCOx activity, thus resulting in stimulation of cellular bioenergetics [29]. Mechanistically, this modification is a nucleophilic displacement, in which the disulfide cysteine residue covalently bounded to glutathione (Cys-SSG) reacts with cyanide, thus promoting the restoration of the free cysteine residue and releasing glutathione as CN-glutathione (CN-SG) [29].

The principal biochemical pathways that are relevant for the reactivity of cyanide in mammalian cells are shown in Fig. 4. Additional, relatively poorly characterized reactions of cyanide in mammalian cells include its ability to react with potential additional reaction(s) with various protein cysteines, for instance in various membrane receptors [65,67]. The strong nucleophilic character of cyanide makes it reactive toward electrophiles, such as carbonyl groups, thus generating cyanohydrin adducts by a nucleophilic addition. For instance, this has been reported for pyruvate and α-ketoglutarate [130,235], whose cyanohydrin conjugate may be used as a potential marker for cyanide exposure. A similar reaction has been reported for cyanide and pyridoxal 5'-phosphate (PLP), as shown by UV-Vis spectroscopy methods. Indeed, the presence of cyanide, a disappearance of a band at 388 nm was seen, characteristic of the aldehyde group in position 4 [236]. Working in homogenates of rat brain tissue, Cassel and colleagues observed a concentration-dependent inhibition of the PLP-dependent enzymes glutamic acid decarboxylase (GAD) and γ-aminobutyric acid transaminase (GABA-T). The enzymatic inactivation was due to the formation of a PLP-CN complex, thus recalling the mechanism of action of classical PLP-dependent enzyme inhibitors, such as amino-oxy compounds [112]. However, the high IC_{50} value (280 μM for GAD) raises some doubt about the physiological relevance of this reaction.

Moreover, the possible interference of cyanide with substrates with carbonyl groups (such as α-ketoglutarate and succinic semialdehyde, both substrates of GABA-T) should be considered [112], thus making cyanide a 'dirty' inhibitor. This notwithstanding the binding of cyanide to PLP, at least in the free form, seems to occur in biological systems as shown by the ability of PLP to act as antidote for cyanide poisoning [237].

Direct reaction on the carbon C-4 of the nicotinamide ring of NAD^+ has also been reported, with different possible biological consequences. For instance, nicotinamide-CN complex formation has been associated with stimulation of ADP-ribosylation, as shown working on the mitochondrial fraction of rat liver [238]. This post-translational modification is enzymatically regulated by ADP-ribosyltransferases, which catalyze the cleavage of NAD^+ and promotes the transfer of ADP-ribose to target proteins. The resulting nicotinamide has been shown to be a potent inhibitor of ADP-ribosyltransferases, and

Fig. 4. Reactions of cyanide in mammalian cells. CN⁻ is a strong-field ligand as well as a strong nucleophile. As such, it is involved in many reactions in mammalian cells. Metal binding: Cyanide is reactive toward transition metals, including iron, zinc, copper, and cobalt, thus binding many metalloproteins (often with an inhibitory effect) and the corrinoid ring of cobalamin. Prodrug activation: The prodrug aurothiomalate, used for the treatment of rheumatoid arthritis, is activated by cyanide and is believed that a CN-gold complex is the actual mediator of its beneficial effect. Cyanohydrin formation: Due to its marked nucleophilicity, cyanide is particularly reactive toward electrophiles, such as carbonyl groups of aldehydes and ketones, thus forming cyanohydrin adducts. *PLP-CN* complex formation: The reaction of cyanide with the aldehydic moiety of PLP has been shown to interfere PLP-dependent enzymes. *NAD⁺-CN* complex formation: The reaction of cyanide with the C-4 of NAD⁺ has been shown to interfere with the activity of some dehydrogenases. Cyanylation: The reaction of cyanide with protein disulfide bridge leads to cyanylation, an emerging post-translational modification suggested to be involved in the regulation of pivotal cellular pathways (*observation made in *Arabidopsis thaliana*). Carbamylation: HCNO has been shown to be involved in cellular aging by carbamylating target proteins, a post-translational modification leading protein misfunctioning. De-glutathionylation: Cyanide reacts with the cysteine-glutathione disulfide of glutathionylated protein, thus displacing glutathione and restoring the protein thiol.

the complex nicotinamide-CN may prevent the enzymatic inhibition [238]. Moreover, although a clear proof of the mechanism of action behind the cyanide-induced increase of ADP-ribosylation still lacks, the fact that cyanide reacts with the nicotinamide ring at pH $\sim$ 8 (which is close to the pH value of the mitochondrial matrix) or higher, may explain why cyanide did not produce any effect on cytosolic ADP-ribosylation [238,239]. The formation of NAD⁺-CN complex has been suggested to be involved in the inhibition of NADH-dependent enzymes such as alcohol dehydrogenase and formate dehydrogenase [240,241]

Finally, higher concentrations of cyanide can produce significant shifts in the intracellular redox state, which, in turn, can affect a variety of cellular reactions, exemplified, for instance in shifts in the cellular NAD⁺/NADH balance [242], as well as various reactions with constituents of the biologically reactive sulfur pool (see below). The potential biological relevance of these reactions remains to be further investigated.

Elimination of cyanide in mammalian cells and organisms

In nature, cyanide catabolism occurs mainly through five main pathways, which can be summarized as (a)

hydrolytic pathway, (b) oxidative pathway, (c) reductive pathway, (d) syntheses pathway, and (e) substitution/transfer pathway as reviewed in [243]. The pathways from a to e are mainly spread in fungi and bacteria, while the substitution/transfer pathway is the only found in mammalians. This catabolic route involves three sulfur metabolizing enzymes, thiosulfate:cyanide sulfurtransferase (TST; also known as rhodanese), 3-mercaptopyruvate sulfurtransferase (3-MST), and sulfide:quinone oxidoreductase (SQR).

TST [EC2.8.1.1] is the main enzyme involved in cyanide detoxification via a reaction which was firstly described in 1933 by Lang *et al.*, who observed in animal tissues the catalytic bioconversion of cyanide and thiosulfate into thiocyanate and sulfite [244]. The enzyme was then referred as rhodanese, from *rhodanid*, the German name of thiocyanate [244]. Its official name is thiosulfate:cyanide sulfurtransferase even if the name 'rhodanese' is still commonly used. The reaction catalyzed by TST takes place through a ping-pong mechanism in which thiosulfate ($S_2O_3^{2-}$) transfers a sulfur atom to a catalytic cysteine, to form a cysteine-persulfide (Cys-SSH) with the concomitant release of sulfite (SO_3^-). The reaction is completed when cyanide reacts with the Cys-SSH, thus producing thiocyanate and regenerating the cysteine in the active site [245]. This reaction offers a rational behind the use of thiosulfate as antidote for cyanide poisoning. TST displays a catalytical efficiency in catabolizing cyanide in the order of 10^3 M^{-1} s^{-1}, with cyanide showing K_M values of $\sim$ 30 mM, although polymorphic variants found in humans show a significant difference in sulfur transfer kinetics [246]. More recently, the role of TST in cyanide detoxification has been re-evaluated because of its predominantly mitochondrial localization and relevant expression levels restricted to liver and kidney, thus leaving other tissue and organs more exposed to cyanide toxicity [247–249].

3-MST [EC2.8.1.2], similarly to TST, is a sulfurtransferase and catalyzes the transfer of a sulfur atom to an acceptor. 3-MST has been widely studied for its role in the biosynthesis of H$_2$S, a small signaling molecule part of the family of gasotransmitters, along with CO and NO [250,251]. Similarly to TST, 3-MST catalyzes a reaction with double displacement mechanism in which 3-mercaptopyruvate binds a cysteine in the active site, thus forming Cys-SSH and eliminating pyruvate. The catalytic cysteine is then restored in the presence of a nucleophile which acts as a sulfur acceptor. Many compounds have been shown to be able, with different efficiency, to work as cosubstrates of MST, such as cyanide (K_M value of $\sim$ 6 mM) and in which case the catalytic efficiency is $\sim$ 400 M^{-1} s^{-1}

[252]. Although it has a catalytical efficiency one order of magnitude lower than TST, 3-MST may play relevant role in cyanide detoxification because of its wider distribution in organs and tissues and its cytosolic localization (rather than merely mitochondrial) [253]. Consistently, are now under evaluation in animal model possible alternative antidotes than thiosulfate, aiming to exploit the 3-MST catalyzed metabolic route. One promising approach seems to be the employment of prodrugs of 3-mercaptopyruvate, because 3-mercaptopyruvate itself appears to be too chemically unstable for such use [254].

SQR [EC1.8.5.8] is a flavoenzyme associated with the inner mitochondrial membrane and it catalyzes the first step of the detoxification pathway of H$_2$S. Following its first identification in the lugworm *Arenicola marina* [255], the role of this enzyme in human physiology has been re-evaluated with the discovery that it displays a sulfide oxidizing activity coupled with electron transfer along the electron transport chain, thus stimulating cellular bioenergetics [256,257]. The reaction mechanism consists in the oxidation of H$_2$S to sulfane sulfur, a reaction which involves two cysteine residues in the active site [258]. Similar to TST and 3-MST, this reaction occurs with a ping-pong mechanism in which the restoration of the free cysteine in the active site occurs in the presence of a nucleophile [259]. The catalytical efficiency of SQR in the presence of cyanide is in the order of 10^7 M^{-1} s^{-1}, thus making of cyanide the most efficient sulfur acceptor for the SQR-catalyzed reaction [260]. This notwithstanding, glutathione has been suggested to be the most physiologically relevant sulfide acceptor, despite the lower efficiency (10^4 M^{-1} s^{-1}), because of the larger abundance in the cellular milieu (in the mM range) [261].

So far, TST has been viewed as the main cyanide detoxifying enzyme, and however, this role is most probably shared with 3-MST. Although SQR has a catalytical efficiency in detoxifying cyanide 4 orders of magnitude higher than TST, its physiological role in cyanide catabolism has been considered negligible because of the low cyanide concentrations as compared to other sulfide acceptors (such as glutathione). However, the observation that cyanide can be catalytically biosynthesized within the mitochondrion [204] may reopen to a possible involvement of SQR-mediated detoxification.

Approximatively 80% of cyanide metabolism is catalyzed by the three sulfur transferases, thus representing the main route of cyanide elimination (which is excreted by the kidneys as thiocyanate) [262]. However, because of cyanide's reactivity, its metabolism is

a complex process, which also involves a plethora of side reactions. As shown in an *in vivo* study, in which the radioactive ^{14}C-labeled sodium cyanide was used to track the metabolic fate of the carbon atom of cyanide in adult rats, it was concluded that (a) cobalamin is responsible in large part for the hepatic detoxification after acute exposure, as suggested by the high amount of cyanocobalamin detected in the urine the first day after the injection, and the subsequent rapid fall observed in the following days; (b) although the catabolic route leading to formation of thiocyanate overall represents the large part of cyanide catabolism, only two-thirds of thiocyanate were found in the urines, thus suggesting that the remaining one-third of the ^{14}C of thiocyanate underwent further reactions before being excreted; (c) 1.7% of cyanide is eliminated by exhalation, of which the 90% in the form of CO_2 and 10% in the form of free cyanide; (d) exists a metabolic equilibrium between cyanide and thiocyanate, as shown in rats by detecting an increase in the levels of exhaled hydrogen cyanide after treatment with radioactive thiocyanate, thus suggesting that thiocyanate can actually be converted to cyanide; (e) cyanide is involved in the one-carbon metabolism, as shown by ^{14}C detection in methyl groups of choline, methionine, formate, and a general distribution in protein and lipids [263].

Cyanide metabolism takes place mainly in the liver, which is the organ with highest abundance in rhodanase and cobalamin. A small amount of cyanide, although non-negligible, takes part in various side reactions. For instance, the oxidation of cyanide to CO_2 has been shown to be a viable metabolic pathway for detoxification and possibly implies the formation of a cyanate (CNO^-) intermediate. As shown *in vivo* experiments, the oxidation of cyanide to cyanate is catalyzed by superoxide dismutase [264], but also MPO may play an additional role [225]. The subsequent metabolic conversion of cyanate into CO_2 has been well characterized in bacteria and plants, and it is catalyzed by cyanase. This enzyme is responsible for the conversion of cyanate, in the presence of bicarbonate as recycling substrate, into carbamate (H_2NCOO^-), which decomposes spontaneously into CO_2 and NH_3 [265]. Although cyanase has not been found in higher organisms, but only in bacteria [266], it is conceivable that a similar reaction may also occur in humans.

Thiocyanate, commonly viewed as a metabolite of cyanide, is 100-fold less toxic than cyanide and is excreted in the urine in about 2.7 days. Biological degradation of thiocyanate to release free cyanide under oxidative conditions (chlorination and ultraviolet disinfection) has been studied, mainly in the field of environmental biology [267]. But the observation that thiocyanate releases free cyanide in an *in vivo* system is somewhat unexpected. To our knowledge, the sulfurtransferase enzymes responsible for the bioconversion of cyanide into thiocyanide are not able to catalyze the reverse reaction (thiocyanate to cyanide). This has been confirmed by Goldstein and co-workers, who first attempted to clarify the biochemical pathway behind the equilibrium between cyanide and thiocyanate. In an experiment carried out in different *in vivo* models (rats, dogs and rabbits), 3 h after the injection of thiocyanate (250–600 mg KSCN/kg), animals were euthanized, and different tissues were homogenized and analyzed for cyanide. Among the tissues studied, namely, liver, kidney, spleen, hearth, lung, striated muscle, stomach, brain and blood, only the latter was positive to the cyanide detection assay. Further experiments carried out also in human blood demonstrated that erythrocytes are the actual site for thiocyanate conversion to cyanide. Although the authors of the study were not able to unequivocally identify the enzyme responsible for this reaction, they named this enzyme thiocyanate oxidase [199]. Independent studies confirmed that cyanide generation could be detected within 10 min after the exposure of human blood cells (but not plasma) to thiocyanate [268]. In a follow-up study, systemic fractionation of hemolysate showed that cyanide formation was present in all the fractions containing hemoglobin, and it was directly proportional the concentration of the enzyme. It was then clear that the oxidation of thiocyanate to cyanide in the erythrocyte is catalyzed by the peroxidase activity of hemoglobin rather than a more specific enzyme. The reaction occurred in the presence of hydrogen peroxide (H_2O_2) and led to the oxidation of thiocyanate to $OSCN^-$, O_2SCN^-, and O_3SCN^- and eventually releasing sulfate and cyanide. This reaction has been shown to be catalyzed by the enzyme in the form of methemoglobin, whose peroxidase activity was relatively high in crude hemolysate (working with excess of H_2O_2), but low in erythrocyte, possibly because of the low concentration of H_2O_2 in the cellular milieu [198].

The finding of the potential involvement of cyanide in the one-carbon metabolism suggests that this molecule is, to some extent, a metabolically active compound. This opens the possibility to a link between cyanide metabolism, the methionine cycle and folate cycle which in turn provide one-carbon units (in the form of methyl groups) for the synthesis of lipids, proteins and DNA. The metabolic link between cyanide and one-carbon metabolism could be formate, a nontetrahydrofolate-linked intermediate of the

one-carbon metabolism [263,269]. Although the involvement of cyanide in the one-carbon metabolism seems to be generally accepted as witnessed by a number of reviews mentioning this pathway [266,270–272], a fundamental—and so far unanswered—question is how cyanide is converted to formate in humans. So far, the metabolic sources of formate in humans are mainly serine and glucose, but also choline, methanol, and formaldehyde [273]. Formate is known to be a metabolic mediator mammals and gut microbiota. Indeed, some bacterial species populating the intestinal flora are able to produce formate through anaerobic fermentation [273]. Interestingly, hydrolytic conversion of cyanide into formate is catalyzed by cyanidase (cyanide dehydratase), an enzyme found in many bacteria, fungi, yeasts and plants [271,272].

As already discussed, cyanide has a marked reactivity for sulfur-containing molecules, particularly for disulfides (R-SS-R) and polysulfides (R-S$_n$H). A similar reaction has been described for cystine, in which case the cyanide-mediated cleavage of the disulfide bond leads to formation of β-thiocyanoalanine intermediate, which undergoes an intramolecular nucleophilic attack with consequent formation of 2-amino-2-thiazoline-4-carboxylic acid, a compound which is currently used as biomarker of cyanide exposure and employed for forensic purposes [179,180].

The principal biochemical pathways that are relevant for the metabolism and elimination of cyanide in mammalian cells are shown in Fig. 5.

Cyanide as a physiological regulator in mammalian cells

In the previous sections, several pathways and mechanisms have been described that result in cyanide production by mammalian cells. The best characterized of these mechanisms being the neutrophil-derived cyanide generation (triggered by neutrophil activation and oxidative burst), and cyanide generation in neurons (a process that generates cyanide basally, in addition, cyanide production can be further enhanced by opioid receptor stimulation). The underlying enzymatic reactions have been outlined in the previous section. However, the question, as to whether cyanide, at endogenous levels, may serve biological regulatory roles has not been explored extensively; the vast majority of the studies exposed cells to cyanide in high (hundreds of micromolar to low millimolar) concentrations and have focused on deleterious effects, such as impairment of bioenergetics and cell death (apoptosis at lower concentrations and necrosis at higher concentrations). Although in the intermediate concentration

range, cyanide was found to activate various cellular signaling pathways (e.g., calcium mobilization), these processes were also predominantly investigated in the context of activation of deleterious pathways (e.g., caspases and endonucleases, inducing DNA fragmentation and apoptosis). Nontoxic cyanide-associated responses that may be best characterized as potentially physiologically relevant were the enhancement of NMDA receptor activation (occurring at 50–100 μM cyanide) [64–67] (given the fact that NMDA receptors play multiple physiological roles) and perhaps a selective stimulation of neurotransmitter release at relatively noncytotoxic concentrations (100 μM) of cyanide from neurons [274]; this action may also be relevant in physiological contexts.

However, three independent lines of more recent studies have extended the investigations of the cellular effects of cyanide into a lower concentration range (nanomolar to low micromolar). These studies support the view that low concentrations of cyanide can exert cytoprotective and beneficial effects in mammalian cells and tissues. (a) Isom's group has investigated the effect of cyanide in PC12 cells *in vitro* and demonstrated that cyanide, in the concentration range of 1–10 μM, causes a rapid-onset, approximately 50% elevation of intracellular IP$_3$ levels. The proposed mechanism involves an early step of extracellular calcium influx into the cells (via a mechanism which remains to be characterized). This calcium signal, in turn, activates phospholipase C, which, in turn, induces IP$_3$ release [68]. IP$_3$, in turn, mobilizes intracellular calcium via its well-known mechanism of action (binding to its receptor on the endoplasmic reticulum and opening calcium channels in its membrane) [275,276]. IP$_3$ is an essential regulator of essential signaling processes, influencing essential cellular functions in health and disease [275,276]. Thus, via regulation of IP$_3$ at low (likely physiological) concentrations, cyanide can potentially regulate a variety of pathways (e.g., a variety of calcium-dependent intracellular enzymes and signal transduction pathways, the Akt-signaling cascade, G-protein-coupled receptor kinase-interacting proteins 1 and 2, mTOR-controlled autophagy pathway, the Bcl-2-family members) and associated processes (ER stress, survival, cell death, gene transcription etc.)

(b) In an independent line of studies, Correira and colleagues exposed RBE4 rat brain endothelial cells and NT2 neuron-like cells to cyanide in the concentration range of 10 nM–1 μM and observed an increase (rather than the usual decrease noted with cytotoxic levels of cyanide) in oxygen consumption of the mitochondria [277]. Already at these low concentrations of

Fig. 5. Elimination pathways of cyanide. CN⁻ is manly catabolized into thiocyanate (SCN⁻) by the sulfurtransferase enzymes and excreted as such in the urine. SCN⁻ exists in a metabolic equilibrium with the cyanide pool. The possible metabolic fates of the cyanide pool include i) interaction with cobalamin, thus forming cyanocobalamin; ii) conversion to formate, which, in turn, can be exhaled as CO_2, excreted in the urine, or take part to the one-carbon metabolism; iii) conversion to HCNO and consequent exhalation as CO_2; iv) exhalation of free CN⁻. Minor pathways involve v) a reaction with cystine and consequent generation of 2-iminothiazolidine-4-carboxylic acid (ITCA), in tautomeric equilibrium with ATCA, and vi) various additional reactions with reactive sulfur species such as persulfides, polysulfides, and nitrosopersulfides.

cyanide, a slight increase in mitochondrial ROS generation was noted, as well as a detectable rearrangement of mitochondrial ultrastructure [277]. Importantly, exposure of the cells to cyanide (at 100 nm and 1 μm concentrations) induced a significant

increase of HIF-1α expression in endothelial cells, as well as an induction of eNOS, VEGF and erythropoietin expression, and increased the ratio of mitochondrial/cytosolic BAX, suggesting that low concentrations of cyanide can affect gene expression

and can induce a preconditioning-type response, which protected the cells from a subsequent cytotoxic insult [277]. These data indicate that cyanide, at nanomolar and low micromolar concentrations, exerts regulatory and cytoprotective, rather than cytotoxic roles in mammalian cells.

(c) Our group has recently investigated the effect of low (nanomolar to micromolar) concentrations of cyanide in HepG2 cells (a human hepatoma line) and observed that cyanide at low (0.1 nM–1 μM) concentrations stimulates mitochondrial electron transport and oxygen consumption, while higher (10 μM and above) concentrations produce the well-established inhibitory effects. Low concentrations of cyanide rapidly (within minutes) increased cellular ATP levels, as confirmed by two independent methods (Extracellular Flux Analysis and a ratiometric intracellular ATP:ADP fluorescent biosensor); the effects of cyanide were attributed to a direct activation of mitochondrial Complex IV (while the activity of Complexes I, II, and III were largely unaffected by cyanide) [57]. The mode of Complex IV activation was attributed to a cyanide-mediated de-glutathionylation of cytochrome C oxidase (via a biochemical mechanism discussed in a previous section) [29]. Low concentrations of cyanide also induced a detectable stimulation of cell proliferation in HepG2 cells as well as in a variety of other human cell lines [29]. The expression of various cyanide-producing and cyanide-metabolizing enzymes was also confirmed in HepG2 cells; interestingly, one of the cyanide-producing enzymes, myeloperoxidase, underwent a biphasic expression change with cyanide: low concentrations induced an upregulation, while higher concentrations produced a downregulation [29].

Taken together, the above studies indicate that low concentrations of cyanide (in the concentration range that is relevant in physiological context) exert significant effects in mammalian cells; these effects include the stimulation of bioenergetics, the stimulation of cell proliferation, and confer a cytoprotective phenotype. Moreover, low, noncytotoxic concentrations of cyanide can significantly affect the expression of multiple gene products, raising the possibility that cyanide (via redox mechanisms, or other pathways) may act as a global regulator of gene expression. The induction of HIF-1α by high (cytotoxic) concentrations of cyanide has been previously observed [278], but the ability of low (nontoxic) concentrations of cyanide to regulate the expression of this factor may be particularly significant in the context of physiological cell responses.

The studies of Hosseini and colleagues [279] may also indirectly support the concept that endogenous cyanide, produced by MPO, may exert stimulatory effects on cellular bioenergetics: these studies, conducted in a tumor cell line, demonstrated that MPO silencing decreases (rather than increases) the cellular bioenergetic profile. One potential interpretation of these findings may be that endogenous, MPO-derived cyanide exerts a basal stimulatory effect on mitochondrial function and cellular bioenergetics.

The spectrum of cyanide's actions in the physiological and pathophysiological contexts, and the associated concentration ranges, are shown in Fig. 6.

Cyanide as a potential novel mammalian gasotransmitter

There is a set of generally accepted criteria that applies to *mammalian gasotransmitters*. [280–284]. According to these criteria, (a) gasotransmitters are small molecules of gas (i.e., they exist in gaseous form or are dissolved in the extracellular or intracellular fluid). They have a small molecular weight, but their derivatives can have different molecular weights and may not necessarily be in gas state. Regardless, these derivatives are still part of the gasotransmitter family. For example, NO qualifies as a gasotransmitter, but also its nongaseous derivatives such as nitrite, nitrate, HNO, or peroxynitrite. Likewise, H_2S is a gaseous molecule, but also its nongaseous derivatives (e.g., polysulfides or thiosulfate) are members of the family. As discussed earlier in the current review, cyanide (HCN) clearly fulfills this criterion, since it is largely in the gaseous state in physiological fluids. (b) Gasotransmitters readily cross cellular membranes. Thus, their movements are not restricted by transporters or membrane receptors, and their cellular actions can involve multiple receptors and targets. As discussed earlier in the current review, cyanide also fulfills this criterion, since it is readily diffusible and has multiple molecular targets. (c) Gasotransmitters are the products of mammalian cells and tissues; they are generated by mammalian enzymes, utilizing endogenous substrates. As discussed earlier at least one enzyme, myeloperoxidase, generates cyanide from endogenous substrates and thus fulfills this criterion. There are also other mammalian enzymes and processes that generate cyanide, for instance from alimentary sources. It is conceivable that future research will identify additional mammalian cyanide-producing enzymes. (d) Importantly, gasotransmitters are expected to be biologically generated in a *regulated* manner. As discussed earlier in the current review, cyanide already meets this criterion, since it is produced in various cell types in regulated manner (e.g., in neurons, opioid receptors, and muscarinic receptors regulate its generation); moreover, it is

Fig. 6. Role of low and high cyanide concentration in the regulation of mammalian cell function in health and disease. At low (nanomolar to low micromolar) concentrations, cyanide exerts beneficial and regulatory roles, for example, stimulation of cellular bioenergetics, induction of a cytoprotective phenotype. At medium concentrations, the effect of cyanide includes the regulation of NMDA receptors and the modulation of intracellular calcium handling, which may either exert physiological or pathophysiological roles, depending on the circumstance. At high (high micromolar to millimolar) concentrations, cyanide induces calcium overload and mitochondrial dysfunction, culminating in apoptotic, or necrotic cell death.

readily diffusible and has multiple molecular targets. However, more work remains to be done in this area to characterize the pathways and mechanisms of regulated cyanide production. (e) Finally, gasotransmitters are expected to fulfill signaling (i.e., biological and physiological) functions (as opposed to toxicological effects) in mammalian cells, at physiologically relevant concentrations; it is also expected that the function of a gasotransmitter can be mimicked by their exogenously applied counterparts. For a long time, cyanide was not considered to fulfill this criterion, since its effects were primarily considered in the toxicological context only. However, as reviewed in the previous sections, there are several independent lines of more recent data showing that cyanide in the nanomolar to single digit micromolar concentrations exerts biological effects that are of regulatory nature (e.g., IP_3 release, stimulation of intracellular calcium mobilization, cytoprotection, regulation of gene expression and stimulation of mitochondrial electron transport and elevation of intracellular ATP levels). Admittedly, the available body of evidence related to the effects of cyanide in this low (nanomolar-to-low micromolar) concentration range is currently relatively small; we believe one of the reasons is that cyanide was not considered as a physiological regulator and its effects at this low concentration range were usually not considered or evaluated.

The current evidence discussed above, as well as another recent commentary [285] suggests that cyanide

may be a viable candidate as a novel endogenous gasotransmitter. Nevertheless, much additional work remains to be done in this area (including the better characterization of endogenous cyanide concentrations in various cells and tissues). Also, substantial work remains to be done focusing on the effect of scavenging endogenous cyanide production or inhibiting or silencing the various endogenous cyanide-producing or cyanide-metabolizing enzymes, to unveil the (likely) dynamic regulation of cyanide by the combination of regulated biosynthesis and multiple pathways of metabolism and elimination.

Other common features of gasotransmitters (including the potential 'recent addition', cyanide) are summarized in Table 2. (Ammonia, and methane, which can also be considered as gaseous mediators, with some caveats, that is ammonia does not appear to have a clear physiological role in mammalian cells and methane does not appear to be generated by mammalian cells from—are discussed in a separate article [284]). These features include the fact that their production occurs across broad representatives of the animal and plant kingdom (including bacteria), relatively short half-life. Typically, these features also include biphasic or bell-shaped effects, whereby high concentrations of these molecules are toxic (while low/endogenously produced concentrations are regulatory). It is the case for NO, CO, H_2S, and now cyanide, that these toxicological effects were recognized first, and the biological roles and endogenous production was

only discovered later. All of the known gasotransmitters have important roles in the regulation of mitochondrial and cellular bioenergetic functions. The gasotransmitter-mediated regulation of mitochondrial function makes a lot of evolutionary sense, given the fact that bacteria already have multiple pathways to generate these mediators, and mitochondria are, from an evolutionary standpoint, modified bacteria.

One of the more contentious issues in gasotransmitter biology is the question of 'absolute concentrations' of these mediators in biological matrices. With respect to cyanide, these concentrations are probably in the low micromolar/high nanomolar range, but these values are dependent on the methods used. Similar to cyanide, the absolute concentrations of H_2S are a matter of ongoing debate, and even the concentrations of CO and NO remain to be further defined. The difficulties in determining these values are partially methodological, partially related to the nature of these molecules. For instance, the reported values for NO and H_2S depend on the ability of the method to include or exclude various reactive NO 'pools' or reactive sulfur 'pools' in the assay. Regardless of the nature of the method, the concentrations of 'free' NO, CO, H_2S, and HCN are probably in the low µM or high nM range; clearly, in these concentrations these molecules are not deleterious to the viability of the cell and serve biological purposes.

Multiple interactions exist between various gasotransmitters

In serving these regulatory roles, there are many interactions between the various gasotransmitters; in addition, they also often interact with various reactive oxygen species. Cyanide, for instance, appears to interact with the NO system in several ways: NO modulates the ability of cyanide to inhibit CCOx [39,60]; moreover, low concentrations of cyanide upregulate NOS expression [277]. Moreover, cyanide appears to interact with the H_2S system through a variety of actions. Thiocyanide can be nonenzymatically produced from the reaction of cyanide and elemental sulfur, polysulfide, or sulfide, or, via the catalysis of 3-MST, it can be generated from cyanide and thiosulfate (a H_2S metabolite).

Also, importantly, 3-MST is not only a cyanide-metabolizing enzyme, but also a H_2S producing enzyme. 3-MST is an oxidant-sensitive enzyme; thus, oxidative inactivation (or downregulation) of 3-MST would not only be expected to suppress cyanide detoxification (to increase its levels), but it would also be expected to inhibit H_2S/persulfide biosynthesis. Of interest,

persulfides are prone to directly react with nucleophiles such as cyanide, thus forming thiocyanate [258]. Because of their disulfide bond, also the hybrid S/N species nitrosopersulfide $SSNO^-$ can react with cyanide to give SNO^- and SCN^- [286,287]. Thiocyanide, can, in turn, regenerate cyanide (for instance via a reaction with hydrogen peroxide). The cold cyanolysis (i.e., nucleophilic attack on a sulfur–sulfur bond by cyanide) [288] may also occur in biological systems with potentially diverse functional consequences. Recently, trisulfide intermediate formation has been observed during the catalytic turnover of SQR, a sufide-catabolizing enzyme which can use cyanide as cosubstrate. Particularly, it has been shown that this enzyme harbors in its active site a cysteine trisulfide and, according to the model proposed by the authors, cyanide interacts with the catalytic trisulfide and removes one sulfur atom by a cyanolysis reaction [289].

The interconnection of the metabolic pathways of cyanide and H_2S may involve also other H_2S-sythesizing enzymes than MST. For instance, cystathionine γ-lyase (CSE), along with CBS, have been shown to be a source of hydropersulfides (RSSH), and their upregulation besides offering protection against oxidative damage [290] may boost cyanide detoxification via both a direct and indirect pathway. For instance, in an in vitro enzymatic coupled assay, it was shown that CSE greatly enhanced the rhodanese-catalyzed bioconversion of cyanide into thiocyanate, by generating cysteine trisulfide (or thiocystine; Cys-SSS-Cys), which serves as a sulfur donor substrate for rhodanese [291]. Interestingly, thiocystine-dependent rhodanese activity has been shown to be 7-fold higher than that in the presence of thiosulfate [289]. Consistently, when injected intravenously, thiocystine protected adult rats from cyanide poisoning [290]. Moreover, as shown in a panel of cell lines, thiocystine proved a marked protection against electrophilic stress, possibly by increasing the bioavailability of pesrulfidated species such as Cys-SSH and GSSH [291]. In turn, persulfides readily react with oxidants such as H_2O_2, resulting in the formation of the unstable intermediate alkyl perthiosulfenic acid (RSSOH), which, in the presence of thiol compounds, leads to regeneration of trisulfide species (R-SSS-R) [292]. Thiocystine has been also shown to directly interact with cyanide thus generating Cys-SSH and Cys-SCN [293–295]. Both CSE and CBS are PLP-dependent enzymes and, although cyanide has been shown to directly react with PLP, thus leading to enzyme inhibition [118], there are no reports suggesting a such reaction in the case of CSE and CBS. The presence of a heme prosthetic group makes the latter enzyme a potential target for small molecule such

Table 2. Comparison of the biological production and cellular action of the gasotransmitters nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H$_2$S), and a potential additional gasotransmitter, hydrogen cyanide (HCN)

	NO	CO	H$_2$S	HCN
Initially characterized as a toxic gas, an environmental hazard?	Yes, it was known to be produced in exhaust fumes from internal combustion engines. A constituent of cigarette smoke.	Yes, it has been long known as a toxic gas emitted from partial combustion of organic molecules; from internal combustion engines, volcanic eruptions, forest fires, household furnaces. A constituent of cigarette smoke.	Yes, it has been recognized as a toxic gas emanating from sewers, swamps and as a toxic byproduct of processes used in paper mills and other industrial processes. Also produced by the normal enteral bacterial flora.	Yes, it has been recognized as a toxic gas used as warfare agent and inhaled during housefires. It is also known as a toxic byproduct of various industrial processes. Also produced via the metabolism of certain alimentary plants.
Produced by plants?	Yes, via reduction of nitrite to NO via different nonenzymatic or enzymatic mechanisms.	Yes, via various heme oxygenase family members.	Yes, via cysteine desulfhydrases and O-acetyl-L-serine (thiol) lyase	Yes, as a (by)product in ethylene and camalexin synthetic pathways and via β-glucosidase from glucosidic cyanogens.
Produced by bacteria?	Yes, via nitrite reductases and NO synthases.	Yes, via various heme oxygenase family members.	Yes, by bacterial isoforms of CBS, CSE and 3-MST and several other pathways.	Yes, via glycine decarboxylation by HCN synthase.
Subsequently discovered as a molecule produced by mammalian cells?	Yes, it is produced from L-arginine by a class of enzymes: nitric oxide synthases (NOS1, NOS2, NOS3). It is also produced by a variety of nonenzymatic processes (e.g., from nitrite).	Yes, it is synthesized from heme, as a product of a class of enzymes: heme oxygenases.	Yes, it is synthesized from L-cysteine, as a product of CBS and CSE and from 3-mercaptopyruvate via 3-MST. It can also be produced via nonenzymatic processes.	Yes, it is synthesized by various mammalian enzymes, for instance myeloperoxidase and likely by other peroxidases. It can also be produced via nonenzymatic processes.
Mammalian endogenous substrate(s)	L-arginine	Heme	L-cysteine, homocysteine, 3-mercaptopyruvate	L-glycine (and likely others)
Pharmacological inhibitors of its production	N-substituted L-arginine derivatives, for example, N^G-methyl-L-arginine (L-NMMA), guanidine derivatives (e.g., aminoguanidine), many others.	Heme oxygenase inhibitors, for example, typically Zn-protoporphyrin-IX.	Aminooxyacetate, beta-cyano-L- alanine and DL-propargylglycine for CBS and CSE and HMPSNE for 3-MST.	Remain to be refined; one possible class of inhibitors may be myeloperoxidase inhibitors.
Diffusible, labile gas?	Yes; breakdown products include nitrite and nitrate. Half-life: seconds. Elimination: via the urine as nitrite and nitrate; also via exhaled air.	Yes. Half-life: hours. (Half-life as CO-Hb: minutes). Elimination: via exhaled air.	Yes, breakdown products include thiosulfate, sulfite and sulfate. Half-life: seconds to minutes. Eliminated: via the urine and via exhaled air.	Yes, breakdown products include thiocyanate. Half-life: minutes to hours. Eliminated: via the urine and via exhaled air.
Reacts with hemoglobin?	Yes; to yield nitrosyl-hemoglobin and methemoglobin.	Yes, to yield carboxy-hemoglobin.	Yes, to yield sulfhemoglobin.	Yes, to yield cyanmethemoglobin.
Free radical?	Yes.	No.	No.	No.
Its 'receptor'.	Guanylate cyclase with high affinity, thiol groups, heme groups; K$_{Ca}$ channels; various other targets.	Guanylate cyclase (with lower affinity than NO); K$_{Ca}$ channels; various other targets.	K$_{ATP}$ channels; phosphodiesterases, various other targets.	NMDA receptors; calcium channels, various other targets.
Does it affect cellular bioenergetics?	Yes, via cytochrome c oxidase and other mitochondrial enzymes and after conversion to	Yes, via inhibition of cytochrome c oxidase and others.	Yes, via inhibition of cytochrome c oxidase and others. At high concentrations it can	Yes, via cytochrome c oxidase (stimulation at very low concentration; inhibition at higher

Table 2. (Continued).

	NO	CO	H₂S	HCN
	peroxynitrite, via the nuclear enzyme poly(ADP-ribose) polymerase.		induce metabolic suppression in cells.	concentration). Its best documented biological and toxicological effect is a metabolic suppression of mammalian cells.
Vasodilatory effects?	Yes, via stimulation of the guanylate/cGMP system, K$_{ATP}$ channel opening, and additional mechanisms.	Yes, via stimulation of the guanylate/cGMP system and additional mechanisms.	Yes, via K$_{ATP}$ channel opening, stimulation of the cGMP system and additional mechanisms.	Yes, at rather high concentrations, most likely via energetic paralysis.
Anti-inflammatory and cytoprotective effects?	Yes, at low concentrations. Higher concentrations are toxic via metabolic inhibition directly or via the formation of secondary products (e.g., peroxynitrite, and subsequent activation of DNA injury, mitochondrial dysfunction and other cell injury pathways).	Yes, at low concentrations, involving MAP kinases and other pathways. Higher concentrations are toxic via metabolic inhibition.	Yes, at low concentrations. Higher concentrations are toxic via induction of metabolic inhibition.	Yes, cytoprotective effects at very low concentrations. Higher concentrations are toxic.

gasotransmitters, as shown for NO and CO [296]. However, despite the similarities shared by these small ligands, CBS is not likely to be targeted by cyanide at physiological conditions, as suggested by the high K$_d$ values (mM range) [297].

There may be complex interactions between NO, H₂S and cyanide on protein cysteines via a combination of nitrosylation, sulfhydration and, possibly, cyanylation reactions; moreover, as discussed earlier, cyanide (after cyanate conversion) can also induce carbamylation of amino groups (ε-amino groups of lysine residue side chains) in proteins. There may be also various interactions on protein glutathionylation; as discussed earlier, cyanide can remove glutathione groups from proteins, while the endogenous, NO-derived nitrosothiol S-nitrosoglutathione can promote protein glutathionylation [27–29,234]. Clearly, the already complex interactions within the so-called "reactive species interactome" [298] will be made even more complex by the addition of cyanide as another physiological and pathophysiological interactor.

Future directions

The traditional areas of cyanide-related research focus on three areas. (a) The first area is the mechanism of cyanide cytotoxicity and organ toxicity. This area has a clear relevance for environmental toxicology and other areas of biology connected to various forms of cyanide intoxication. As discussed in the previous sections, work in this area (utilizing direct administration of exogenous cyanide to cells, isolated organs or animals) has identified a significant number of interrelated mechanisms, although full integration of the various pathophysiological pathways and mechanisms remains to be completed. One of the questions that remains to be further clarified, is how much of cyanide cytotoxicity is downstream of mitochondrial inhibition, and how much is triggered by actions of cyanide on other cellular effectors. Much more work remains to be performed in the field related to the role of cyanide in the bacterial–mammalian cell interactions, for example, in the context of cystic fibrosis (where, for instance, direct studies attempting to neutralize bacterial cyanide generation) are missing. In other potential *Pseudomonas*-associated diseases (e.g., urinary tract infection or systemic inflammation / sepsis), there are presently no direct studies, although the experimental tools (strains of cyanide-production deficient *Pseudomonas*, cyanide scavengers, etc.) are readily available. (b) The second area of future investigations relates to the field of the generation of cyanide-sensitive probes and improved methods to detect cyanide in biological fluids or in cells. Given its potential toxicity and environmental hazard, many techniques for cyanide detection have been developed, ranging from rough methods such as necked eye detection methods to more quantitative techniques like gas chromatography/mass spectrometry. This notwithstanding, few methods combine high levels of sensitivity, selectivity,

and ease of application, as reviewed in [299]. Overall, as compared to colorimetric techniques, fluorescent-based detection methods offer a higher sensitivity, with a detection limit which can reach the order of 10 nM. However, the selectivity studies for these probes are carried out only toward few compounds such as F^-, Cl^-, Br^-, I^-, just to mention a few, while the cellular milieu is a complex matter and interference with other strong nucleophiles not always can be predicted, for this reason colorimetric methods are still a good alternative. Since methods for the detection of cyanide in biological systems (e.g., cells in culture) are less developed, and a gold standard cyanide probe, which is selective, sensitive and cell permeable (i.e., suitable to detect endogenously produced cyanide in living cells) remains to be established. (c) The third traditional area of cyanide research relates to the improvement of pharmacological tools and clinically used drugs suitable for the therapy of cyanide intoxication. As discussed elsewhere [14,15], there are many classes of drugs or potential drug development candidates for this purpose, but the efficacy of these agents needs to be improved and the therapeutic window of administration needs to be extended. In this respect, it would be important to take a renewed focus on potential fresh and new approaches that may be suitable to displace cyanide from CCOx to reactivate mitochondrial electron transport and aerobic ATP generation.

(d) For at least three decades now, significant interest has been generated related to the potential anti-cancer effect of various plant-based cyanogenic glycosides, for instance, laetrile or amygdalin (contained in apricot kernels). However, comprehensive meta-analysis reveals that the potential efficacy of laetrile or amygdalin in cancer patients is not currently supported by sound clinical data [300–302]. At the same time, there is a significant risk of serious adverse effects from cyanide poisoning after laetrile or amygdalin administration [300–302]. Although the above approach, as a therapeutic direction, does not appear to bear fruit, it is clear from multiple *in vitro* studies that cancer cells can be killed or metabolically inhibited by either cyanogenic glycosides and/or by authentic cyanide [303] (although the concentrations required for such effects do not appear to be different from the concentrations required for the same effect in normal cells). Nevertheless, the possibility remains that there may also be some potential future utility in exploiting the toxicological effects of cyanide in the context of tumor therapy, especially if future approaches could selectively target the cytotoxic action of cyanide to the tumor cells and tumor tissue; there are some

preclinical studies that produced encouraging data in this direction [304,305].

Regarding more novel, and nontraditional areas, (e) there should be a new interest to further investigate the biological effects of low (noncytotoxic) concentrations of cyanide in various biological systems. These studies could focus on cytoprotective effects, the regulation of mitochondrial function and global cellular metabolomics, and perhaps the ability of low-dose cyanide to produce a safe and effective method for a preconditioning-type cytoprotective effect. The pathways and effectors involved in the effects of low-dose cyanide in various cell types (in health and disease) also remain to be established. Likewise, (f) the biochemical reactions involved in the effects of cyanide in biological (regulatory) contexts remains to be further studied. For instance, does cyanide induce cyanylation in mammalian cells and tissues? (All of the required biochemical effectors for this post-translational modification appear to exist in mammalian cells.) (g) Additionally, the question whether cyanide can induce de-glutathionylation of targets other than CCOx should be investigated. Glutathionylation is an emerging field of post-translational protein modification, with significant roles in cell signaling and cell metabolism; it is conceivable that cyanide interacts with this system in multiple ways. (h) Moreover, the pathways and enzymes involved in endogenous (mammalian) cyanide generation should be further investigated. How are the known cyanide-producing enzymes (e.g., myeloperoxidase) regulated in biological contexts? Are there conditions where the known cyanide-degrading enzymes may work in 'reverse' and may contribute to the generation of cyanide in mammalian cells? Are there additional cyanide-producing mammalian enzymes? What are the exact pathways and enzymatic reactions that contribute to receptor-mediated or receptor-regulated endogenous cyanide generation in neurons? How do the above mechanisms become affected in various diseases, or during physiological aging? (i) Finally, how does endogenously produced cyanide interact with the other gasotransmitter systems on already known targets (CCOx, globins, etc.) or on other common cellular targets in health and disease? Further work in these areas is expected to clarify this question and may open a new direction in gasotransmitter biology.

Acknowledgements

Conflict of interest

The authors declare no conflict of interest.

Author contributions

CS conceived and CS and KZ wrote the manuscript.

References

1 Oracz K, El-Maarouf-Bouteau H, Bogatek R, Corbineau F & Bailly C (2008) Release of sunflower seed dormancy by cyanide: cross-talk with ethylene signalling pathway. *J Exp Bot* **59**, 2241–2251.

2 García I, Gotor C & Romero LC (2014) Beyond toxicity: a regulatory role for mitochondrial cyanide. *Plant Signal Behav* **9**, e27612.

3 Yu L, Liu Y & Xu F (2019) Comparative transcriptome analysis reveals significant differences in the regulation of gene expression between hydrogen cyanide- and ethylene-treated Arabidopsis thaliana. *BMC Plant Biol* **19**, 92.

4 García I, Arenas-Alfonseca L, Moreno I, Gotor C & Romero LC (2019) HCN regulates cellular processes through posttranslational modification of proteins by S-cyanylation. *Plant Physiol* **179**, 107–123.

5 Gotor C *et al*. (2019) Signaling by hydrogen sulfide and cyanide through post-translational modification. *J Exp Bot* **70**, 4251–4265.

6 Knowles CJ (1976) Microorganisms and cyanide. *Bacteriol Rev* **40**, 652–680.

7 Carterson AJ *et al*. (2004) The transcriptional regulator AlgR controls cyanide production in Pseudomonas aeruginosa. *J Bacteriol* **186**, 6837–6844.

8 Blumer C & Haas D (2000) Mechanism, regulation, and ecological role of bacterial cyanide biosynthesis. *Arch Microbiol* **173**, 170–177.

9 Zdor RE (2015) Bacterial cyanogenesis: impact on biotic interactions. *J Appl Microbiol* **118**, 267–274.

10 Yan H *et al*. (2019) Conditional quorum-sensing induction of a cyanide-insensitive terminal oxidase stabilizes cooperating populations of Pseudomonas aeruginosa. *Nat Commun* **10**, 4999.

11 Egekeze JO & Oehme FW (1980) Cyanides and their toxicity: A literature review. *Vet Q* **2**, 104–114.

12 Simeonova FP & Fishbein L (2004) Hydrogen cyanide and cyanides: human health aspects. Available from. http://www.who.int/iris/handle/10665/42942.

13 Geller RJ, Barthold C, Saiers JA & Hall AH (2006) Pediatric cyanide poisoning: causes, manifestations, management, and unmet needs. *Pediatrics* **118**, 2146–2158.

14 Petrikovics I, Budai M, Kovacs K & Thompson DE (2015) Past, present and future of cyanide antagonism research: From the early remedies to the current therapies. *World J Methodol* **5**, 88–100.

15 Hendry-Hofer TB, Ng PC, Witeof AE, Mahon SB, Brenner M, Boss GR & Bebarta VS (2019) A review on ingested cyanide: risks, clinical presentation, diagnostics, and treatment challenges. *J Med Toxicol* **15**, 128–133.

16 Keilin D (1966) The History of cell respiration and cytochrome. Cambridge University Press, New York.

17 Battelli F & Stern L (1911) Die Oxydation der Bernsteinsäure durch Tiergewebe. *Biochem Zeitschr* **30**, 172–178.

18 Warburg O (1923) Über die Grundlagen der Wielandschen Atmungstheorie. *Biochem Zeitschr* **142**, 518.

19 Warburg O (1928) Über die chemische Konstitution des Atmungsferments. *Naturwissenschaften* **16**, 345–350.

20 Keilin D (1929) Cytochrome and respiratory enzymes. *Proc R Soc Lond B* **104**, 206–252.

21 Keilin D, Hartree EF & Hartree EF (1939) Cytochrome and cytochrome oxidase. *Proc R Soc Lond B* **127**, 167–191.

22 Albaum HG, Tepperman J & Bodansky O (1946) The in vivo inactivation by cyanide of brain cytochrome oxidase and its effect on glycolysis and on the high energy phosphorus compounds in brain. *J Biol Chem* **164**, 45–51.

23 Sarti P, Forte E, Mastronicola D, Giuffrè A & Arese M (2012) Cytochrome c oxidase and nitric oxide in action: molecular mechanisms and pathophysiological implications. *Biochim Biophys Acta* **1817**, 610–619.

24 Tsukihara T *et al*. (2003) The low-spin heme of cytochrome c oxidase as the driving element of the proton-pumping process. *Proc Natl Acad Sci USA* **100**, 15304–15309.

25 Napiwotzki J, Shinzawa-Itoh K, Yoshikawa S & Kadenbach B (1997) ATP and ADP bind to cytochrome c oxidase and regulate its activity. *Biol Chem* **378**, 1013–1021.

26 Hüttemann M, Lee I, Grossman LI, Doan JW & Sanderson TH (2012) Phosphorylation of mammalian cytochrome c and cytochrome c oxidase in the regulation of cell destiny: respiration, apoptosis, and human disease. *Adv Exp Med Biol* **748**, 237–264.

27 Dalle-Donne I, Rossi R, Colombo G, Giustarini D & Milzani A (2009) Protein S-glutathionylation: a regulatory device from bacteria to humans. *Trends Biochem Sci* **34**, 85–96.

28 Fratelli M *et al*. (2003) Identification of proteins undergoing glutathionylation in oxidatively stressed hepatocytes and hepatoma cells. *Proteomics* **3**, 1154–1161.

29 Randi EB, Zuhra K, Pecze L, Panagaki T & Szabo C (2021) Physiological concentrations of cyanide stimulate mitochondrial Complex IV and enhance

cellular bioenergetics. *Proc Natl Acad Sci USA* **118**, e2026245118.

30 Brookes PS (2004) Mitochondrial nitric oxide synthase. *Mitochondrion* **3**, 187–204.

31 Yoshikawa S, Muramoto K, Shinzawa-Itoh K, Aoyama H, Tsukihara T, Ogura T, Shimokata K, Katayama Y & Shimada H (2006) Reaction mechanism of bovine heart cytochrome c oxidase. *Biochim Biophys Acta* **1757**, 395–400.

32 Brunori M, Giuffre A & Sarti P (2005) Cytochrome c oxidase, ligands and electrons. *J Inorg Biochem* **99**, 324–336.

33 Yonetani T & Ray GS (1965) Studies on cytochrome oxidase: VI. Kinetics of the aerobic oxidation of ferrocytochrome c by cytochrome oxidase. *J Biol Chem* **240**, 3392–3398.

34 Jones MG, Bickar D, Wilson MT, Brunori M, Colosimo A & Sarti P (1984) A re-examination of the reactions of cyanide with cytochrome c oxidase. *Biochem J* **220**, 57–66.

35 Wilson MT, Antonini G, Malatesta F, Sarti P & Brunori M (1994) Probing the oxygen binding site of cytochrome c oxidase by cyanide. *J Biol Chem* **269**, 24114–24119.

36 Muramoto K, Ohta K, Shinzawa-Itoh K, Kanda K, Taniguchi M, Nabekura H, Yamashita E, Tsukihara T & Yoshikawa S (2010) Bovine cytochrome c oxidase structures enable O_2 reduction with minimization of reactive oxygens and provide a proton-pumping gate. *Proc Natl Acad Sci USA* **107**, 7740–7745.

37 Gibson QH & Greenwood C (1963) Reactions of cytochrome oxidase with oxygen and carbon monoxide. *Biochem J* **86**, 541.

38 Nicholls P (1975) The effect of sulphide on cytochrome aa3. Isosteric and allosteric shifts of the reduced alpha-peak. *Biochim Biophys Acta* **396**, 24–35.

39 Pearce LL, Bominaar EL, Hill BC & Peterson J (2003) Reversal of cyanide inhibition of cytochrome c oxidase by the auxiliary substrate nitric oxide: an endogenous antidote to cyanide poisoning? *J Biol Chem* **278**, 52139–52145.

40 Sarti P *et al.* (2000) Nitric oxide and cytochrome c oxidase: mechanisms of inhibition and NO degradation. *Biochem Biophys Res Commun* **274**, 183–187.

41 Nůsková H, Vrbacký M, Drahota Z & Houštěk J (2010) Cyanide inhibition and pyruvate-induced recovery of cytochrome c oxidase. *J Bioenerg Biomembr* **42**, 395–403.

42 Gee SJ, Green CE & Tyson CA (1990) Cyanide-induced cytotoxicity to isolated hepatocytes. *Toxicol In Vitro* **4**, 37–45.

43 Yamamoto H (1989) Hyperammonemia, increased brain neutral and aromatic amino acid levels, and encephalopathy induced by cyanide in mice. *Toxicol Appl Pharmacol* **99**, 415–420.

44 Holtzman D, Offutt M, Tsuji M, Neuringer LJ & Jacobs D (1993) Creatine kinase-catalyzed reaction rate in the cyanide-poisoned mouse brain. *J Cereb Blood Flow Metab* **13**, 153–161.

45 Katsumata Y, Sato K, Yada S, Suzuki O & Yoshino M (1983) Kinetic analysis of anaerobic metabolism in rats during acute cyanide poisoning. *Life Sci* **33**, 151–155.

46 Decorps M, Lebas JF, Leviel JL, Confort S, Remy C & Benabid AL (1984) Analysis of brain metabolism changes induced by acute potassium cyanide intoxication by 31P NMR in vivo using chronically implanted surface coils. *FEBS Lett* **168**, 1–6.

47 Hattori H, Suzuki Y, Fujimiya T, Yamamoto K & Ueda M (1986) Acute effects of carbon monoxide and cyanide on hepatic mitochondrial function. *Z Rechtsmed* **96**, 1–10.

48 MacMillan VH (1989) Cerebral energy metabolism in cyanide encephalopathy. *J Cereb Blood Flow Metab* **9**, 156–162.

49 Maduh EU, Nealley EW, Song H, Wang PC & Baskin SI (1995) A protein kinase C inhibitor attenuates cyanide toxicity in vivo. *Toxicology* **100**, 129–137.

50 Ikegaya H, Iwase H, Hatanaka K, Sakurada K, Yoshida K & Takatori T (2001) Diagnosis of cyanide intoxication by measurement of cytochrome c oxidase activity. *Toxicol Lett* **119**, 117–123.

51 Marziaz ML, Frazier K, Guidry PB, Ruiz RA, Petrikovics I & Haines DC (2013) Comparison of brain mitochondrial cytochrome c oxidase activity with cyanide LD_{50} yields insight into the efficacy of prophylactics. *J Appl Toxicol* **33**, 50–55.

52 Singh P, Rao P, Yadav SK, Gujar NL, Satpute RM & Bhattacharya R (2015) Time- and temperature-dependent changes in cytochrome c oxidase activity and cyanide concentration in excised mice organs and mice cadavers. *J Forensic Sci* **60**, S162–170.

53 Younes M & Strubelt O (1988) Cyanide-induced injury to the isolated perfused rat liver. *Pharmacol Toxicol* **63**, 382–385.

54 Pham JC, Huang DT, McGeorge FT & Rivers EP (2007) Clarification of cyanide's effect on oxygen transport characteristics in a canine model. *Emerg Med J* **24**, 152–156.

55 Honma M, Okada Y, Suzuki H, Mori A & Ishiyama I (1992) The effect of cyanide on isolated perfused rat heart. *Nihon Hoigaku Zasshi* **46**, 121–125.

56 Aw TY & Jones DP (1989) Cyanide toxicity in hepatocytes under aerobic and anaerobic conditions. *Am J Physiol* **257**, C435–441.

57 Maduh EU, Borowitz JL & Isom GE (1991) Cyanide-induced alteration of the adenylate energy pool in a rat neurosecretory cell line. *J Appl Toxicol* **11**, 97–101.

58 Niknahad H & O'Brien PJ (2008) Mechanism of sulfite cytotoxicity in isolated rat hepatocytes. *Chem Biol Interact* **174**, 147–154.

59 Li L, Prabhakaran K, Mills EM, Borowitz JL & Isom GE (2005) Enhancement of cyanide-induced mitochondrial dysfunction and cortical cell necrosis by uncoupling protein-2. *Toxicol Sci* **86**, 116–124.

60 Leavesley HB, Li L, Prabhakaran K, Borowitz JL & Isom GE (2008) Interaction of cyanide and nitric oxide with cytochrome c oxidase: implications for acute cyanide toxicity. *Toxicol Sci* **101**, 101–111.

61 Hariharakrishnan J, Satpute RM, Prasad GB & Bhattacharya R (2009) Oxidative stress mediated cytotoxicity of cyanide in LLC-MK2 cells and its attenuation by alpha-ketoglutarate and N-acetyl cysteine. *Toxicol Lett* **185**, 132–141.

62 Dalal P & Romani A (2010) Adenosine triphosphate depletion by cyanide results in a Na^+-dependent Mg^{2+} extrusion from liver cells. *Metabolism* **59**, 1663–1671.

63 Yamagiwa T, Inokuchi S, Saito T, Inoue S, Morita S & Kawaguchi AT (2013) A stable in vitro method for assessing the toxicity of potassium cyanide and its antidote. *Tokai J Exp Clin Med* **38**, 114–122.

64 Cai Z & McCaslin PP (1992) Selective effects of cyanide (100 microM) on the excitatory amino acid-induced elevation of intracellular calcium levels in neuronal culture. *Neurochem Res* **17**, 803–808.

65 Arden SR, Sinor JD, Potthoff WK & Aizenman E (1998) Subunit-specific interactions of cyanide with the N-methyl-D-aspartate receptor. *J Biol Chem* **273**, 21505–21511.

66 Sun P, Rane SG, Gunasekar PG, Borowitz JL & Isom GE (1997) Modulation of the NMDA receptor by cyanide: enhancement of receptor-mediated responses. *J Pharmacol Exp Ther* **280**, 1341–1348.

67 Sun P, Rane SG, Gunasekar PG, Borowitz JL & Isom GE (1999) Cyanide interaction with redox modulatory sites enhances NMDA receptor responses. *J Biochem Mol Toxicol* **13**, 253–259.

68 Yang CW, Borowitz JL, Gunasekar PG & Isom GE (1996) Cyanide-stimulated inositol 1,4,5-trisphosphate formation: an intracellular neurotoxic signaling cascade. *J Biochem Toxicol* **11**, 251–256.

69 Johnson JD, Conroy WG & Isom GE (1987) Alteration of cytosolic calcium levels in PC12 cells by potassium cyanide. *Toxicol Appl Pharmacol* **88**, 217–224.

70 Borowitz JL, Born GS & Isom GE (1988) Potentiation of evoked adrenal catecholamine release by cyanide: possible role of calcium. *Toxicology* **50**, 37–45.

71 Maduh EU, Turek JJ, Borowitz JL, Rebar A & Isom GE (1990) Cyanide-induced neurotoxicity: calcium mediation of morphological changes in neuronal cells. *Toxicol Appl Pharmacol* **103**, 214–221.

72 Kanthasamy AG, Maduh EU, Peoples RW, Borowitz JL & Isom GE (1991) Calcium mediation of cyanide-induced catecholamine release: implications for neurotoxicity. *Toxicol Appl Pharmacol* **110**, 275–282.

73 Maduh EU, Porter DW & Baskin SI (1993) Calcium antagonists. A role in the management of cyanide poisoning? *Drug Saf* **9**, 237–248.

74 Zhang L, Li L, Leavesley HW, Zhang X, Borowitz JL & Isom GE (2010) Cyanide-induced apoptosis of dopaminergic cells is promoted by BNIP3 and Bax modulation of endoplasmic reticulum-mitochondrial Ca^{2+} levels. *J Pharmacol Exp Ther* **332**, 97–105.

75 Patel MN, Yim GK & Isom GE (1992) Potentiation of cyanide neurotoxicity by blockade of ATP-sensitive potassium channels. *Brain Res* **593**, 114–116.

76 Gunasekar PG, Sun PW, Kanthasamy AG, Borowitz JL & Isom GE (1996) Cyanide-induced neurotoxicity involves nitric oxide and reactive oxygen species generation after N-methyl-D-aspartate receptor activation. *J Pharmacol Exp Ther* **277**, 150–155.

77 Gunasekar PG, Borowitz JL & Isom GE (1998) Cyanide-induced generation of oxidative species: involvement of nitric oxide synthase and cyclooxygenase-2. *J Pharmacol Exp Ther* **285**, 236–241.

78 Mills EM, Gunasekar PG, Pavlakovic G & Isom GE (1996) Cyanide-induced apoptosis and oxidative stress in differentiated PC12 cells. *J Neurochem* **67**, 1039–1046.

79 Nicotera P, Thor H & Orrenius S (1989) Cytosolic free calcium and cell killing in hepatoma 1C1C7 cells exposed to chemical anoxia. *FASEB J* **3**, 59–64.

80 Yang CW, Rathinavelu A, Borowitz JL & Isom GE (1994) Activation of a calcium- and pH-dependent phospholipase A2 by cyanide in PC12 cells. *Toxicol Appl Pharmacol* **124**, 262–267.

81 Lee SJ, Kwon CH & Kim YK (2009) Alterations in membrane transport function and cell viability induced by ATP depletion in primary cultured rabbit renal proximal tubular cells. *Korean J Physiol Pharmacol* **13**, 15–22.

82 Bhattacharya R & Lakshmana Rao PV (1997) Cyanide induced DNA fragmentation in mammalian cell cultures. *Toxicology* **123**, 207–215.

83 Yamamoto HA & Mohanan PV (2002) Melatonin attenuates brain mitochondria DNA damage induced by potassium cyanide in vivo and in vitro. *Toxicology* **179**, 29–36.

84 Zemlyak I, Sapolsky R & Gozes I (2009) NAP protects against cyanide-related microtubule destruction. *J Neural Transm* **116**, 1411–1416.

85 Chao KF, Liu SH & Lin-Shiau SY (1996) Suppression of potassium currents by cyanide on the mouse motor nerve terminals. *Neurosci Lett* **203**, 105–108.

86 Inoue M, Sakamoto Y, Yano A & Imanaga I (1997) Cyanide suppression of inwardly rectifying K+ channels in guinea pig chromaffin cells involves dephosphorylation. *Am J Physiol* **273**, C137–147.

87 Shou Y, Gunasekar PG, Borowitz JL & Isom GE (2000) Cyanide-induced apoptosis involves oxidative-

stress-activated NF-kappaB in cortical neurons. *Toxicol Appl Pharmacol* **164**, 196–205.

88 Shou Y, Li N, Li L, Borowitz JL & Isom GE (2002) NF-κB-mediated up-regulation of Bcl-X(S) and Bax contributes to cytochrome c release in cyanide-induced apoptosis. *J Neurochem* **81**, 842–852.

89 Patel MN, Yim GK & Isom GE (1992) Blockade of N-methyl-D-aspartate receptors prevents cyanide-induced neuronal injury in primary hippocampal cultures. *Toxicol Appl Pharmacol* **115**, 124–129.

90 Prabhakaran K, Li L, Mills EM, Borowitz JL & Isom GE (2005) Up-regulation of uncoupling protein 2 by cyanide is linked with cytotoxicity in mesencephalic cells. *J Pharmacol Exp Ther* **314**, 1338–1345.

91 Prabhakaran K, Li L, Zhang L, Borowitz JL & Isom GE (2007) Upregulation of BNIP3 and translocation to mitochondria mediates cyanide-induced apoptosis in cortical cells. *Neuroscience* **150**, 159–167.

92 Prabhakaran K, Li L, Borowitz JL & Isom GE (2004) Caspase inhibition switches the mode of cell death induced by cyanide by enhancing reactive oxygen species generation and PARP-1 activation. *Toxicol Appl Pharmacol* **195**, 194–202.

93 Ardelt BK, Borowitz JL, Maduh EU, Swain SL & Isom GE (1994) Cyanide-induced lipid peroxidation in different organs: subcellular distribution and hydroperoxide generation in neuronal cells. *Toxicology* **89**, 127–137.

94 Ardelt B, Borowitz JL, & Isom GE (1989) Brain lipid peroxidation and antioxidant protectant mechanisms following acute cyanide intoxication. *Toxicology* **56**, 147–154.

95 Maduh EU, Borowitz JL & Isom GE (1990) Cyanide-induced alteration of cytosolic pH: involvement of cellular hydrogen ion handling processes. *Toxicol Appl Pharmacol* **106**, 201–208.

96 Patel MN, Ardelt BK, Yim GK & Isom GE (1991) Cyanide induces Ca^{2+}-dependent and -independent release of glutamate from mouse brain slices. *Neurosci Lett* **131**, 42–44.

97 Persson SA, Cassel G & Sellström A (1985) Acute cyanide intoxication and central transmitter systems. *Fundam Appl Toxicol* **5**, S150–159.

98 Patel MN, Peoples RW, Yim GK & Isom GE (1994) Enhancement of NMDA-mediated responses by cyanide. *Neurochem Res* **19**, 1319–1323.

99 Jones DC, Gunasekar PG, Borowitz JL & Isom GE (2000) Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells. *J Neurochem* **74**, 2296–2304.

100 Jones DC, Prabhakaran K, Li L, Gunasekar PG, Shou Y, Borowitz JL & Isom GE (2003) Cyanide enhancement of dopamine-induced apoptosis in mesencephalic cells involves mitochondrial dysfunction and oxidative stress. *Neurotoxicology* **24**, 333–342.

101 Cassel GE, Koch M & Tiger G (1995) The effects of cyanide on the extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, 5-hydroxyindoleacetic acid and inositol phospholipid breakdown in the brain. *Neurotoxicology* **16**, 73–82.

102 Kanthasamy AG, Ardelt B, Malave A, Mills EM, Powley TL, Borowitz JL & Isom GE (1997) Reactive oxygen species generated by cyanide mediate toxicity in rat pheochromocytoma cells. *Toxicol Lett* **93**, 47–54.

103 Prabhakaran K, Li L, Borowitz JL & Isom GE (2002) Cyanide induces different modes of death in cortical and mesencephalon cells. *J Pharmacol Exp Ther* **303**, 510–519.

104 Bello-Reuss E, Grady TP & Reuss L (1981) Mechanism of the effect of cyanide on cell membrane potentials in Necturus gall-bladder epithelium. *J Physiol* **314**, 343–357.

105 Richter C & Schlegel J (1993) Mitochondrial calcium release induced by prooxidants. *Toxicol Lett* **67**, 119–127.

106 Bhattacharya R & Rao PVL (2001) Pharmacological interventions of cyanide-induced cytotoxicity and DNA damage in isolated rat thymocytes and their protective efficacy in vivo. *Toxicol Lett* **119**, 59–70.

107 Salhany JM, Stohs SJ, Reinke LA, Pieper GM & Hassing JM (1979) ^{31}P nuclear magnetic resonance of metabolic changes associated with cyanide intoxication in the perfused rat liver. *Biochem Biophys Res Commun* **86**, 1077–1083.

108 Way JL *et al.* (1984) Recent perspectives on the toxicodynamic basis of cyanide antagonism. *Fundam Appl Toxicol* **4**, S231–239.

109 Sun MK & Reis DJ (1994) Hypoxia-activated Ca^{2+} currents in pacemaker neurons of rat rostral ventrolateral medulla in vitro. *J Physiol* **476**, 101–116.

110 Elliott AC, Smith GL & Allen DG (1989) Simultaneous measurements of action potential duration and intracellular ATP in isolated ferret hearts exposed to cyanide. *Circ Res* **64**, 583–591.

111 Aitken PG & Braitman DJ (1989) The effects of cyanide on neural and synaptic function in hippocampal slices. *Neurotoxicology* **10**, 239–247.

112 Adler M, Lebeda FJ, Kauffman FC & Deshpande SS (1999) Mechanism of action of sodium cyanide on rat diaphragm muscle. *J Appl Toxicol* **19**, 411–419.

113 Cheung JY, Merali S, Wang J, Zhang X-Q, Song J, Merali C, Tomar D, You H, Judenherc-Haouzi A & Haouzi P (2019) The central role of protein kinase C epsilon in cyanide cardiotoxicity and its treatment. *Toxicol Sci* **171**, 247–257.

114 Pavlaković G, Eyer CL & Isom GE (1995) Neuroprotective effects of PKC inhibition against chemical hypoxia. *Brain Res* **676**, 205–211.

115 Rathinavelu A, Sun P, Pavlakovic G, Borowitz JL & Isom GE (1994) Cyanide induces protein kinase C

translocation: blockade by NMDA antagonists. *J Biochem Toxicol* **9**, 235–240.

116 Prohaska JR, Oh SH, Hoekstra WG & Ganther HE (1977) Glutathione peroxidase: inhibition by cyanide and release of selenium. *Biochem Biophys Res Commun* **74**, 64–71.

117 Solomonson LP (1981) Cyanide as a metabolic inhibitor. In Cyanide in Biology (Vennesland B, Conn EE, Knowles CJ, Westley J & Wissing F, eds). Academic Press, New York.

118 Cassel G, Karlsson L & Sellström A (1991) On the inhibition of glutamic acid decarboxylase and gamma-aminobutyric acid transaminase by sodium cyanide. *Pharmacol Toxicol* **69**, 238–241.

119 Blair-Johnson M, Fiedler T & Fenna R (2001) Human myeloperoxidase: structure of a cyanide complex and its interaction with bromide and thiocyanate substrates at 1.9 A resolution. *Biochemistry* **40**, 13990–13997.

120 Iñarrea P (2002) Purification and determination of activity of mitochondrial cyanide-sensitive superoxide dismutase in rat tissue extract. *Methods Enzymol* **349**, 106–114.

121 Cassel GE, Persson SA & Stenström A (1994) Effects of cyanide in vitro on the activity of monoamine oxidase in striatal tissue from rat and pig. *Biochem Pharmacol* **47**, 499–504.

122 Patriarca P, Dri P, Kakinuma K & Rossi F (1976) Studies on the mechanism of metabolic stimulation in polymorphonuclear leukocytes during phagocytosis. Activators and inhibitors of the granule bound NADPH oxidase. *Mol Cell Biochem* **12**, 137–146.

123 DeChatelet LR, McPhail LC & Shirley PS (1977) Effect of cyanide on NADPH oxidation by granules from human polymorphonuclear leukocytes. *Blood* **49**, 445–454.

124 Heyneman RA & Vercauteren RE (1984) Activation of a NADPH oxidase from horse polymorphonuclear leukocytes in a cell-free system. *J Leukoc Biol* **36**, 751–759.

125 Clark RA, Leidal KG, Pearson DW & Nauseef WM (1987) NADPH oxidase of human neutrophils. Subcellular localization and characterization of an arachidonate-activatable superoxide-generating system. *J Biol Chem* **262**, 4065–4074.

126 Kamendulis LM, Zhang H, Wang Y & Klaunig JE (2002) Morphological transformation and oxidative stress induced by cyanide in Syrian hamster embryo (SHE) cells. *Toxicol Sci* **68**, 437–443.

127 Robinson CP, Baskin SI, Groff WA & Franz DR (1984) Cyanide loss from tissue baths in the presence and absence of tissue. *Toxicol Lett* **21**, 305–308.

128 Nielsen TH, Olsen NV, Toft P & Nordström CH (2013) Cerebral energy metabolism during mitochondrial dysfunction induced by cyanide in piglets. *Acta Anaesthesiol Scand* **57**, 793–801.

129 Laing RA, Chiba K, Tsubota K & Oak SS (1992) Metabolic and morphologic changes in the corneal endothelium. The effects of potassium cyanide, iodoacetamide, and ouabain. *Invest Ophthalmol Vis Sci* **33**, 3315–3324.

130 Niknahad H, Khan S, Sood C & O'Brien PJ (1994) Prevention of cyanide-induced cytotoxicity by nutrients in isolated rat hepatocytes. *Toxicol Appl Pharmacol* **128**, 271–279.

131 Uchida K & Doi K (1994) Glycolysis vs. respiration as ATP source for the shape of quiescent cardiomyocytes. *Respir Physiol* **97**, 213–223.

132 Shiroyama K, Moriwaki K, Kusunoki S, Saeki N & Yuge O (2001) Glucose loading during primary culture has opposite effects on the viability of hepatocytes exposed to potassium cyanide and to iodoacetic acid. *Metabolism* **50**, 342–348.

133 Thompson RW, Valentine HL & Valentine WM (2003) Cytotoxic mechanisms of hydrosulfide anion and cyanide anion in primary rat hepatocyte cultures. *Toxicology* **188**, 149–159.

134 Ray P, Monroe FL, Berman JD & Fiedler J (1991) Cyanide sensitive and insensitive bioenergetics in a clonal neuroblastoma x glioma hybrid cell line. *Neurochem Res* **16**, 1121–1124.

135 Lash LH, Tokarz JJ, Chen Z, Pedrosi BM & Woods EB (1996) ATP depletion by iodoacetate and cyanide in renal distal tubular cells. *J Pharmacol Exp Ther* **276**, 194–205.

136 Isom GE, Liu DH & Way JL (1975) Effect of sublethal doses of cyanide on glucose catabolism. *Biochem Pharmacol* **24**, 871–875.

137 Davies JC (2002) Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence. *Paediatr Respir Rev* **3**, 128–134.

138 Garcia-Clemente M, de la Rosa D, Máiz L, Girón R, Blanco M, Olveira C, Canton R & Martinez-García MA (2020) Impact of Pseudomonas aeruginosa infection on patients with chronic inflammatory airway diseases. *J Clin Med* **9**, 3800.

139 Rossi E *et al.* (2021) Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis. *Nat Rev Microbiol* **19**, 331–342.

140 Zlosnik JE & Williams HD (2004) Methods for assaying cyanide in bacterial culture supernatant. *Lett Appl Microbiol* **38**, 360–365.

141 Zlosnik JEA, Tavankar GR, Bundy JG, Mossialos D, O'Toole R & Williams HD (2006) Investigation of the physiological relationship between the cyanide-insensitive oxidase and cyanide production in Pseudomonas aeruginosa. *Microbiology* **152**, 1407–1415.

142 Williams HD, Zlosnik JE & Ryall B (2007) Oxygen, cyanide and energy generation in the cystic fibrosis pathogen Pseudomonas aeruginosa. *Adv Microb Physiol* **52**, 1–71.

143 Anderson RD, Roddam LF, Bettiol S, Sanderson K & Reid DW (2010) Biosignificance of bacterial cyanogenesis in the CF lung. *J Cyst Fibros* **9**, 158–164.

144 Chen W, Roslund K, Fogarty CL, Pussinen PJ, Halonen L, Groop P-H, Metsälä M & Lehto M (2016) Detection of hydrogen cyanide from oral anaerobes by cavity ring down spectroscopy. *Sci Rep* **6**, 22577.

145 Eiserich JP, Ott SP, Kadir T, Morrissey BM, Hayakawa KA, La Merrill MA & Cross CE (2018) Quantitative assessment of cyanide in cystic fibrosis sputum and its oxidative catabolism by hypochlorous acid. *Free Radic Biol Med* **129**, 146–154.

146 Enderby B, Smith D, Carroll W & Lenney W (2009) Hydrogen cyanide as a biomarker for Pseudomonas aeruginosa in the breath of children with cystic fibrosis. *Pediatr Pulmonol* **44**, 142–147.

147 Gilchrist FJ (2013) Hydrogen cyanide concentrations in the breath of adult cystic fibrosis patients with and without Pseudomonas aeruginosa infection. *J Breath Res* **7**, 26010.

148 Smith D, Spaněl P, Gilchrist FJ & Lenney W (2013) Hydrogen cyanide, a volatile biomarker of Pseudomonas aeruginosa infection. *J Breath Res* **7**, 44001.

149 Gilchrist FJ (2015) Exhaled breath hydrogen cyanide as a marker of early Pseudomonas aeruginosa infection in children with cystic fibrosis. *ERJ Open Res* **1**, 44–2015.

150 Lauridsen RK, Sommer LM, Johansen HK, Rindzevicius T, Molin S, Jelsbak L, Engelsen SB & Boisen A (2017) SERS detection of the biomarker hydrogen cyanide from Pseudomonas aeruginosa cultures isolated from cystic fibrosis patients. *Sci Rep* **7**, 45264.

151 Smith D & Španěl P (2017) On the importance of accurate quantification of individual volatile metabolites in exhaled breath. *J Breath Res* **11**, 47106.

152 Voggu L et al. (2006) Microevolution of cytochrome bd oxidase in Staphylococci and its implication in resistance to respiratory toxins released by Pseudomonas. *J Bacteriol* **188**, 8079–8086.

153 Bernier SP, Workentine ML, Li X, Magarvey NA, O'Toole GA & Surette MG (2016) Cyanide toxicity to Burkholderia cenocepacia is modulated by polymicrobial communities and environmental factors. *Front Microbiol* **7**, 725.

154 Nair C, Shoemark A, Chan M, Ollosson S, Dixon M, Hogg C, Alton EWFW, Davies JC & Williams HD (2014) Cyanide levels found in infected cystic fibrosis sputum inhibit airway ciliary function. *Eur Respir J* **44**, 1253–1261.

155 Ryall B, Davies JC, Wilson R, Shoemark A & Williams HD (2008) Pseudomonas aeruginosa, cyanide accumulation and lung function in CF and non-CF bronchiectasis patients. *Eur Respir J* **32**, 740–747.

156 Pruskowski KA, Britton GW & Cancio LC (2020) Outcomes after the administration of hydroxocobalamin. *Int J Burns Trauma* **10**, 231–236.

157 Gao L, Zhang Y, Wang Y, Qiao X, Zi J, Chen C & Wan Y (2016) Reduction of PCN biosynthesis by NO in Pseudomonas aeruginosa. *Redox Biol* **8**, 252–258.

158 Stutz MD, Gangell CL, Berry LJ, Garratt LW, Sheil B & Sly PD (2011) Cyanide in bronchoalveolar lavage is not diagnostic for Pseudomonas aeruginosa in children with cystic fibrosis. *Eur Respir J* **37**, 553–558.

159 Neerincx AH, Mandon J, van Ingen J, Arslanov DD, Mouton JW, Harren FJM, Merkus PJFM & Cristescu SM (2015) Real-time monitoring of hydrogen cyanide (HCN) and ammonia (NH_3) emitted by Pseudomonas aeruginosa. *J Breath Res* **9**, 27102.

160 Darby C, Cosma CL, Thomas JH & Manoil C (1999) Lethal paralysis of Caenorhabditis elegans by Pseudomonas aeruginosa. *Proc Natl Acad Sci USA* **96**, 15202–15207.

161 Gallagher LA & Manoil C (2001) Pseudomonas aeruginosa PAO1 kills Caenorhabditis elegans by cyanide poisoning. *J Bacteriol* **183**, 6207–6214.

162 Broderick KE, Chan A, Balasubramanian M, Feala J, Reed SL, Panda M, Sharma VS, Pilz RB, Bigby TD & Boss GR (2008) Cyanide produced by human isolates of Pseudomonas aeruginosa contributes to lethality in Drosophila melanogaster. *J Infect Dis* **197**, 457–464.

163 Al-Hasan MN, Wilson JW, Lahr BD, Eckel-Passow JE & Baddour LM (2008) Incidence of Pseudomonas aeruginosa bacteremia: a population-based study. *Am J Med* **121**, 702–708.

164 Babich T (2020) Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study. *Int J Antimicrob Agents* **55**, 105847.

165 Kosai K, Yamagishi Y, Hashinaga K, Nakajima K, Mikamo H, Hiramatsu K, Takesue Y & Yanagihara K (2020) Multicenter surveillance of the epidemiology of gram-negative bacteremia in Japan. *J Infect Chemother* **26**, 193–198.

166 Persoon MC (2020) Mortality associated with carbapenem-susceptible and Verona Integron-encoded Metallo-beta-lactamase-positive Pseudomonas aeruginosa bacteremia. *Antimicrob Resist Infect Control* **9**, 25.

167 Xu H ((2020) Prognostic role of time to positivity of blood culture in children with Pseudomonas aeruginosa bacteremia. *BMC Infect Dis* **20**, 665.

168 Rapoport RM & Murad F (1984) Effect of cyanide on nitrovasodilator-induced relaxation, cyclic GMP accumulation and guanylate cyclase activation in rat aorta. *Eur J Pharmacol* **104**, 61–70.

169 Mathew R, Burke-Wolin T, Gewitz MH & Wolin MS (1991) O_2 and rat pulmonary artery tone: effects of

endothelium, Ca^{2+}, cyanide, and monocrotaline. *J Appl Physiol* **1985** , 30–36.

170 Clark JF, Matsumoto T & Nakayama S (2000) Intact smooth muscle metabolism: its responses to cyanide poisoning and pyruvate stimulation. *Front Biosci* **5**, A18–23.

171 Ozolu RI, Okolie NP, Ebeigbe AB & Karikari N (2007) Effects of sub-chronic oral cyanide on endothelial function in rabbit aortic rings. *Hum Exp Toxicol* **26**, 105–110.

172 Kiss L, Deitch EA & Szabo C (2008) Hydrogen sulfide decreases adenosine triphosphate levels in aortic rings and leads to vasorelaxation via metabolic inhibition. *Life Sci* **83**, 589–594.

173 Lundquist P, Rosling H & Sörbo B (1988) The origin of hydrogen cyanide in breath. *Arch Toxicol* **61**, 270–274.

174 Baud FJ (1991) Elevated blood cyanide concentrations in victims of smoke inhalation. *N Engl J Med* **325**, 1761–1766.

175 Vinnakota CV, Peetha NS, Perrizo MG, Ferris DG, Oda RP, Rockwood GA & Logue BA (2012) Comparison of cyanide exposure markers in the biofluids of smokers and non-smokers. *Biomarkers* **17**, 625–633.

176 Swezey R, Shinn W, Green C, Drover DR, Hammer GB, Schulman SR, Zajicek A, Jett DA & Boss GR (2013) Comparison of a new cobinamide-based method to a standard laboratory method for measuring cyanide in human blood. *J Anal Toxicol* **37**, 382–385.

177 Mani J, Rutz J, Maxeiner S, Juengel E, Bon D, Roos F, Chun FK-H & Blaheta RA (2019) Cyanide and lactate levels in patients during chronic oral amygdalin intake followed by intravenous amygdalin administration. *Complement Ther Med* **43**, 295–299.

178 Ishii A, Seno H, Watanabe-Suzuki K, Suzuki O & Kumazawa T (1998) Determination of cyanide in whole blood by capillary gas chromatography with cryogenic oven trapping. *Anal Chem* **70**, 4873–4876.

179 Yu JC (2012) LC-MS/MS analysis of 2-aminothiazoline-4-carboxylic acid as a forensic biomarker for cyanide poisoning. *World J Methodol* **2**, 33–41.

180 Giebułtowicz J, Rużycka M, Fudalej M, Krajewski P & Wroczyński P (2016) LC-MS/MS method development and validation for quantitative analyses of 2-aminothiazoline-4-carboxylic acid–a new cyanide exposure marker in post mortem blood. *Talanta* **150**, 586–592.

181 Youso SL, Rockwood GA & Logue BA (2012) The analysis of protein-bound thiocyanate in plasma of smokers and non-smokers as a marker of cyanide exposure. *J Anal Toxicol* **36**, 265–269.

182 Spanel P, Dryahina K & Smith D (2007) Acetone, ammonia and hydrogen cyanide in exhaled breath of several volunteers aged 4–83 years. *J Breath Res* **1**, 11–l4.

183 Spanel P, Dryahina K & Smith D (2007) The concentration distributions of some metabolites in the exhaled breath of young adults. *J Breath Res* **1**, 1–8.

184 Stamyr K, Vaittinen O, Jaakola J, Guss J, Metsälä M, Johanson G & Halonen L (2009) Background levels of hydrogen cyanide in human breath measured by infrared cavity ring down spectroscopy. *Biomarkers* **14**, 285–291.

185 Anseeuw K, Delvau N, Burillo-Putze G, De Iaco F, Geldner G, Holmström P, Lambert Y & Sabbe M (2013) Cyanide poisoning by fire smoke inhalation: a European expert consensus. *Eur J Emerg Med* **20**, 2–9.

186 Koyama K (1997) Abnormal cyanide metabolism in uraemic patients. *Nephrol Dial Transplant* **12**, 1622–1628.

187 Htike TT, Moriya F & Miyaishi S (2019) Cyanide concentrations in blood and tissues of fire victims. *Leg Med* **41**, 101628.

188 Hasuike Y, Nakanishi T, Moriguchi R, Otaki Y, Nanami M, Hama Y, Naka M, Miyagawa K, Izumi M & Takamitsu Y (2004) Accumulation of cyanide and thiocyanate in haemodialysis patients. *Nephrol Dial Transplant* **19**, 1474–1479.

189 Yeats TH (2018) Setting and diffusing the cyanide bomb in plant defense. *Plant Physiol* **178**, 956–957.

190 Aratani Y (2018) Myeloperoxidase: its role for host defense inflammation and neutrophil function. *Arch Biochem Biophys* **640**, 47–52.

191 Winterbourn CC, Kettle AJ & Hampton MB (2016) Reactive oxygen species and neutrophil function. *Annu Rev Biochem* **85**, 765–792.

192 Zgiczyński JM & Stelmaszyńska T (1979) Hydrogen cyanide and cyanogen chloride formation by the myeloperoxidase-H$_2$O$_2$-Cl$^-$ system. *Biochim Biophys Acta* **567**, 309–314.

193 Stelmaszyńska T (1986) Formation of HCN and its chlorination to ClCN by stimulated human neutrophils–2 Oxidation of thiocyanate as a source of HCN. *Int J Biochem* **18**, 1107–1114.

194 Steck N & Grassl GA (2014) Free Radicals and Pathogens – Role for Reactive Intermediates in Innate Immunity. In Systems Biology of Free Radicals and Antioxidant (Laher I, ed). Springer, Berlin, Heidelberg.

195 Kim J, Gherasim C & Banerjee R (2008) Decyanation of vitamin B12 by a trafficking chaperone. *Proc Natl Acad Sci USA* **105**, 14551–14554.

196 Lerner-Ellis JP (2006) Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. *Nat Genet* **38**, 93–100.

197 Shinnar S & Singer HS (1984) Cobalamin C mutation (methylmalonic aciduria and homocystinuria) in adolescence: a treatable cause of dementia and myelopathy. *N Engl J Med* **311**, 451–454.

198 Chung J & Wood JL (1971) Oxidation of thiocyanate to cyanide catalyzed by hemoglobin. *J Biol Chem* **246**, 555–560.

199 Goldstein F & Rieders F (1953) Conversion of thiocyanate to cyanide by an erythrocytic enzyme. *Am J Physiol* **173**, 287–290.

200 Shan G & Hammock BD (2001) Development of sensitive esterase assays based on α-cyano-containing esters. *Anal Biochem* **299**, 54–62.

201 El Hadri L, Chanas B & Ghanayem BI (2005) Comparative metabolism of methacrylonitrile and acrylonitrile to cyanide using cytochrome P4502E1 and microsomal epoxide hydrolase-null mice. *Toxicol Appl Pharmacol* **205**, 116–125.

202 Morant AV, Bjarnholt N, Kragh ME, Kjaergaard CH, Jørgensen K, Paquette SM, Piotrowski M, Imberty A, Olsen CE, Møller BL *et al.* (2010) The β-glucosidases responsible for bioactivation of hydroxynitrile glucosides in Lotus Japonicus. *Plant Physiol* **147**, 1072–1091.

203 Stelmaszyńska T & Zgliczyński JM (1981) In: Cyanide in Biology (1st edn), pp. 371–383. Academic Press, London.

204 Stelmaszyńska T (1985) Formation of HCN by human phagocytosing neutrophils–1. Chlorination of Staphylococcus epidermidis as a source of HCN. *Int J Biochem* **17**, 373–379.

205 Graham GG & Dale MM (1990) The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes–II. Evidence for the formation and biological activity of aurocyanide. *Biochem Pharmacol* **39**, 1697–1702.

206 Rudkowski R, Graham GG, Champion GD & Ziegler JB (1990) The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes–I. The effects of aurocyanide on the oxidative burst of polymorphonuclear leukocytes. *Biochem Pharmacol* **39**, 1687–1695.

207 Graham GG & Kettle AJ (1998) The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes. III. The formation of aurocyanide by myeloperoxidase. *Biochem Pharmacol* **56**, 307–312.

208 Stelmaszyńska T & Zgliczyński JM (1978) N-(2-Oxoacyl)amino acids and nitriles as final products of dipeptide chlorination mediated by the myeloperoxidase/H$_2$O$_2$/Cl$^-$ system. *Eur J Biochem* **92**, 301–308.

209 Borowitz JL, Gunasekar PG & Isom GE (1997) Hydrogen cyanide generation by mu-opiate receptor activation: possible neuromodulatory role of endogenous cyanide. *Brain Res* **768**, 294–300.

210 Gunasekar PG, Borowitz JL, Turek JJ, Van Horn DA & Isom GE (2000) Endogenous generation of cyanide in neuronal tissue: involvement of a peroxidase system. *J Neurosci Res* **61**, 570–575.

211 Gunasekar PG, Prabhakaran K, Li L, Zhang L, Isom GE & Borowitz JL (2004) Receptor mechanisms mediating cyanide generation in PC12 cells and rat brain. *Neurosci Res* **49**, 13–18.

212 Long L, Huang M, Wang N, Wu Y, Wang K, Gong A, Zhang Z & Sessler JL (2018) A mitochondria-specific fluorescent probe for visualizing endogenous hydrogen cyanide fluctuations in neurons. *J Am Chem Soc* **140**, 1870–1875.

213 Sosa-Torres ME & Kroneck PM (2009) Interaction of cyanide with enzymes containing vanadium manganese non-heme iron and zinc. *Met Ions Life Sci* **6**, 363–393.

214 Fanelli AR, Antonini E & Caputo A (1964) Hemoglobin and myoglobin. *Adv Protein Chem* **19**, 73–222.

215 Savenkova ML, Mueller DM & Heinecke JW (1994) Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. *J Biol Chem* **269**, 20394–20400.

216 Swope SK, Chasteen ND, Weber KE & Harris DC (1988) Low-spin cyanide adduct of transferrin. *J Am Chem Soc* **110**, 3835–3840.

217 Shearer J, Fitch SB, Kaminsky W, Benedict J, Scarrow RC & Kovacs JA (2003) How does cyanide inhibit superoxide reductase? Insight from synthetic FeIIIN4S model complexes. *Proc Natl Acad Sci USA* **100**, 3671–3676.

218 Paci M, Desideri A & Rotilio G (1988) Cyanide binding to Cu Zn superoxide dismutase. An NMR study of the Cu (II) Co (II) derivative. *J Biol Chem* **263**, 162–166.

219 Keilin D & Mann T (1940) Carbonic anhydrase. Purification and nature of the enzyme. *Biochem J* **34**, 1163–1176.

220 Ackermann BP & Ahlers J (1976) Kinetics of alkaline phosphatase from pig kidney. Influence of complexing agents on stability and activity. *Biochem J* **153**, 151–157.

221 Hayward GC, Hill HAO, Pratt JM, Vanston NJ & Williams RJP (1965) The chemistry of vitamin B 12 Part IV The thermodynamic trans-effect. *J Chem Soc* **1196**, 6485–6493.

222 Jaisson S, Pietrement C & Gillery P (2018) Protein carbamylation: chemistry pathophysiological involvement and biomarkers. *Adv Clin Chem* **84**, 1–38.

223 Gorisse L, Pietrement C, Vuiblet V, Schmelzer CEH, Köhler M, Duca L, Debelle L, Fornès P, Jaisson S & Gillery P (2016) Protein carbamylation is a hallmark of aging. *Proc Natl Acad Sci USA* **113**, 1191–1196.

224 Dirnhuber P & Schütz F (1948) The isomeric transformation of urea into ammonium cyanate in aqueous solutions. *Biochem J* **42**, 628–632.

225 Delporte C, Boudjeltia KZ, Furtmüller PG, Maki RA, Dieu M, Noyon C, Soudi M, Dufour D, Coremans C,

Nuyens V *et al*. (2018) Myeloperoxidase-catalyzed oxidation of cyanide to cyanate: A potential carbamylation route involved in the formation of atherosclerotic plaques? *J Biol Chem* **293**, 6374–6386.

226 Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA & Hazen SL (2007) Protein carbamylation links inflammation smoking uremia and atherogenesis. *Nat Med* **13**, 1176–1184.

227 Sirpal S (2009) Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease. *Clin Sci* **116**, 681–695.

228 Parker AJ & Kharasch N (1959) The scission of the sulfur-sulfur bond. *Chem Rev* **59**, 583–628.

229 Gawron O & Fernando J (1961) Kinetics of the cyanide-cystine reaction. *J Am Chem Soc* **83**, 2906–2908.

230 Gawron O (1966) On the reaction of cyanide with cystine and cystine peptides. The chemistry of organic sulfur compounds. (Eds.: Kharasch N, Myers CL), Oxford: Pergamon, 351-365.

231 Thomas ML, Janatova J, Gray WR & Tack BF (1982) Third component of human complement: localization of the internal thiolester bond. *Proc Natl Acad Sci USA* **79**, 1054–1058.

232 Price NC (1976) Alternative products in the reaction of 2-nitro-5-thiocyanatobenzoic acid with thiol groups. *Biochem J* **159**, 177–180.

233 Fasco MJ, Hauer CR, Stack RF, Ohehir C, Barr JR & Eadon GA (2007) Cyanide adducts with human plasma proteins: albumin as a potential exposure surrogate. *Chem Res Toxicol* **20**, 677–684.

234 Xiong Y, Uys JD, Tew KD & Townsend DM (2011) S-glutathionylation: from molecular mechanisms to health outcomes. *Antioxid Redox Signal* **15**, 233–270.

235 Kanthasamy AG, Rathinavelu A, Borowitz JL & Isom GE (1994) Interaction of cyanide with a dopamine metabolite: formation of a cyanohydrin adduct and its implications for cyanide-induced neurotoxicity. *Neurotoxicology* **15**, 887–895.

236 Bonavita V (1960) The reaction of pyridoxal 5-phosphate with cyanide and its analytical use. *Arch Biochem* **88**, 366–372.

237 Keniston RC, Cabellon S Jr & Yarbrough KS (1987) Pyridoxal 5′-phosphate as an antidote for cyanide, spermine, gentamicin, and dopamine toxicity: An in vivo rat study. *Toxicol Appl Pharmacol* **88**, 433–441.

238 Masmoudi A, Mandel P & Malviya AN (1988) Unexpected stimulation of mitochondrial ADP-ribosylation by cyanide. *FEBS Lett* **237**, 150–154.

239 Brüne B & Lapetina EG (1989) Activation of a cytosolic ADP-ribosyltransferase by nitric oxide-generating agents. *J Biol Chem* **264**, 8455–8458.

240 Kaplan NO, Ciotti MM & Stolzenbach FE (1954) The action of hydroxylamine and cyanide on alcohol dehydrogenase of horse liver. *J Biol Chem* **211**, 419–429.

241 Ohyama T & Yamazaki I (1975) Formate dehydrogenase. Subunit and mechanism of inhibition by cyanide and azide. *J Biochem* **77**, 845–852.

242 Olson LE, Merker MP, Patel MK, Bongard RD, Daum JM, Johns RA & Dawson CA (2000) Cyanide increases reduction but decreases sequestration of methylene blue by endothelial cells. *Ann Biomed Eng* **28**, 85–93.

243 Gupta N, Balomajumder C & Agarwal VK (2010) Enzymatic mechanism and biochemistry for cyanide degradation: a review. *J Hazard Mater* **176**, 1–13.

244 Lang K (1933) Die rhodanbildung im tierkörper. *Biochem Z* **259**, 262–266.

245 Cipollone R, Ascenzi P & Visca P (2007) Common themes and variations in the rhodanese superfamily. *IUBMB Life* **59**, 51–59.

246 Libiad M, Sriraman A & Banerjee R (2015) Polymorphic variants of human rhodanese exhibit differences in thermal stability and sulfur transfer kinetics. *J Biol Chem* **290**, 23579–23588.

247 Aminlari M, Malekhusseini A, Akrami F & Ebrahimnejad H (2007) Cyanide-metabolizing enzyme rhodanese in human tissues: comparison with domestic animals. *Comp Clin Pathol* **16**, 47–51.

248 Baskin SI, Horowitz AM & Nealley EW (1992) The antidotal action of sodium nitrite and sodium thiosulfate against cyanide poisoning. *J Clin Pharmacol* **32**, 368–375.

249 Alexander K, Procell LR, Kirby SD & Baskin SI (1989) The inactivation of rhodanese by nitrite and inhibition by other anions in vitro. *J Biochem Toxicol* **4**, 29–33.

250 Augsburger F & Szabo C (2020) Potential role of the 3-mercaptopyruvate sulfurtransferase (3-MST)—hydrogen sulfide (H$_2$S) pathway in cancer cells. *Pharmacol Res* **154**, 104083.

251 Pedre B, Dick TP (2020) 3-Mercaptopyruvate sulfurtransferase: an enzyme at the crossroads of sulfane sulfur trafficking. *Biol Chem* **402**, 223–2.

252 Yadav PK, Yamada K, Chiku T, Koutmos M & Banerjee R (2013) Structure and kinetic analysis of H$_2$S production by human mercaptopyruvate sulfurtransferase. *J Biol Chem* **288**, 20002–20013.

253 Tomita M, Nagahara N & Ito T (2016) Expression of 3-mercaptopyruvate sulfurtransferase in the mouse. *Molecules* **21**, 1707.

254 Nagasawa HT, Goon DJ, Crankshaw DL, Vince R & Patterson SE (2007) Novel orally effective cyanide antidotes. *J Med Chem* **50**, 6462–6464.

255 Hildebrandt TM & Grieshaber MK (2008) Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. *FEBS J* **275**, 3352–3361.

256 Goubern M, Andriamihaja M, Nübel T, Blachier F & Bouillaud F (2007) Sulfide the first inorganic substrate for human cells. *FASEB J* **21**, 1699–1706.

257 Módis K, Coletta C, Erdélyi K, Papapetropoulos A & Szabo C (2013) Intramitochondrial hydrogen sulfide production by 3-mercaptopyruvate sulfurtransferase maintains mitochondrial electron flow and supports cellular bioenergetics. *FASEB J* **27**, 601–611.

258 Marcia M, Ermler U, Peng G, Michel H (2010) A new structure-based classification of sulfide: quinone oxidoreductases. *Proteins* **78**, 1073–108.

259 Jackson MR, Melideo SL & Jorns MS (2012) Human sulfide: quinone oxidoreductase catalyzes the first step in hydrogen sulfide metabolism and produces a sulfane sulfur metabolite. *Biochemistry* **51**, 6804–6815.

260 Libiad M, Yadav PK, Vitvitsky V, Martinov M & Banerjee R (2014) Organization of the human mitochondrial hydrogen sulfide oxidation pathway. *J Biol Chem* **289**, 30901–30910.

261 Forman HJ, Zhang H & Rinna A (2009) Glutathione: overview of its protective roles, measurement, and biosynthesis. *Mol Aspects Med* **30**, 1–12.

262 Abraham K, Buhrke T & Lampen A (2016) Bioavailability of cyanide after consumption of a single meal of foods containing high levels of cyanogenic glycosides: a crossover study in humans. *Arch Toxicol* **90**, 559–574.

263 Boxer GE & Rickards JC (1952) Studies on the metabolism of the carbon of cyanide and thiocyanate. *Arch Biochem Biophys* **39**, 7–26.

264 Johnson JD & Isom GE (1985) The oxidative disposition of potassium cyanide in mice. *Toxicology* **37**, 215–224.

265 Johnson WV & Anderson PM (1987) Bicarbonate is a recycling substrate for cyanase. *J Biol Chem* **262**, 9021–9025.

266 Anderson PM, Sung YC & Fuchs PM (1990) The cyanase operon and cyanate metabolism. *FEMS Microbiol Rev* **7**, 247–52.

267 Zheng A, Dzombak DA & Luthy RG (2004) Effects of thiocyanate on the formation of free cyanide during chlorination and ultraviolet disinfection of publicly owned treatment works secondary effluent. *Water Environ Res* **76**, 205–212.

268 Pines KL & Crymble MM (1952) In vitro conversion of thiocyanate to cyanide in the presence of erythrocytes. *Proc Soc Exp Biol Med* **81**, 160–162.

269 Brosnan ME & Brosnan JT (2016) Formate: The neglected member of one-carbon metabolism. *Annu Rev Nutr* **36**, 369–388.

270 Ansell M & Lewis FA (1970) A review of cyanide concentrations found in human organs. A survey of literature concerning cyanide metabolism, 'normal', non-fatal, and fatal body cyanide levels. *J Forensic Med* **17**, 148–155.

271 Hall AH, Isom GE & Rockwood GA. (2007) Toxicology of cyanides and cyanogens. John Wiley & Sons (2015). European Centre for Ecotoxicology and Toxicology of Chemicals. ECETOC JACC REPORT n. 53: hydrogen cyanide, sodium and potassium cyanides and acetone cyanohydrin. CAS n. 74-90-8, 143-33-9, 151-50-8 and 75-86-5.

272 Jaszczak E, Polkowska Ż, Narkowicz S & Namieśnik J (2017) Cyanides in the environment-analysis-problems and challenges. *Environ Sci Pollut Res Int* **24**, 15929–15948.

273 Pietzke M, Meiser J & Vazquez A (2020) Formate metabolism in health and disease. *Mol Metab* **33**, 23–37.

274 McCaslin PP & Yu XZ (1992) Cyanide selectively augments kainate- but not NMDA-induced release of glutamate and taurine. *Eur J Pharmacol* **228**, 73–75.

275 Ivanova H, Vervliet T, Ivanova H, Decuypere J-P, De Smedt H, Missiaen L, Bultynck G & Parys JB (2014) Inositol 1,4,5-trisphosphate receptor-isoform diversity in cell death and survival. *Biochim Biophys Acta* **1843**, 2164–2183.

276 Thillaiappan NB, Chakraborty P, Hasan G & Taylor CW (2019) IP$_3$ receptors and Ca^{2+} entry. *Biochim Biophys Acta Mol Cell Res* **1866**, 1092–1100.

277 Correia SC (2012) Cyanide preconditioning protects brain endothelial and NT2 neuron-like cells against glucotoxicity: role of mitochondrial reactive oxygen species and HIF-1α. *Neurobiol Dis* **45**, 206–218.

278 Zhang L (2007) HIF-1alpha activation by a redox-sensitive pathway mediates cyanide-induced BNIP3 upregulation and mitochondrial-dependent cell death. *Free Radic Biol Med* **43**, 117–127.

279 Hosseini M, Rezvani HR, Aroua N, Bosc C, Farge T, Saland E, Guyonnet-Dupérat V, Zaghdoudi S, Jarrou L, Larrue C et al. (2019) Targeting myeloperoxidase disrupts mitochondrial redox balance and overcomes cytarabine resistance in human acute myeloid leukemia. *Cancer Res* **79**, 5191–5203.

280 Wang R (2002) Two's company, three's a crowd – Can H$_2$S be the third endogenous gaseous transmitter? *FASEB J* **16**, 1792–1798.

281 Szabo C (2010) Gaseotransmitters: new frontiers for translational science. *Sci Transl Med* **2**, 59ps54.

282 Kolluru GK, Shen X, Yuan S & Kevil CG (2017) Gasotransmitter heterocellular signaling. *Antioxid Redox Signal* **26**, 936–960.

283 Wang R. (2018) Overview of Gasotransmitters and the Related Signaling Network. Gasotransmitters (Metallobiology series no. 12) Ed: Rui W. Royal Society of Chemistry: London. 1-28.

284 Wang R (2014) Gasotransmitters: growing pains and joys. *Trends Biochem Sci* **39**, 227–232.

285 Pacher P (2021) Cyanide emerges as an endogenous mammalian gasotransmitter. *Proc Natl Acad Sci USA* **118**, e2108040118.

286 Fukuto JM (2018) Biological hydropersulfides and related polysulfides - a new concept and perspective in redox biology. *FEBS Lett* **592**, 2140–2152.

287 Wedmann R, Ivanovic-Burmazovic I & Filipovic MR (2017) Nitrosopersulfide (SSNO⁻) decomposes in the presence of sulfide, cyanide or glutathione to give HSNO/SNO⁻: consequences for the assumed role in cell signalling. *Interface Focus* **7**, 20160139.

288 Greiner R & Dick TP (2015) Real-time assays for monitoring the influence of sulfide and sulfane sulfur species on protein thiol redox states. *Methods Enzymol* **555**, 57–77.

289 Landry AP, Moon S, Bonanata J, Cho US, Coitiño EL & Banerjee R (2020) Dismantling and rebuilding the trisulfide cofactor demonstrates its essential role in human sulfide quinone oxidoreductase. *J Am Chem Soc* **142**, 14295–14306.

290 Zuhra K, Tomé CS, Forte E, Vicente JB & Giuffrè A (2021) The multifaceted roles of sulfane sulfur species in cancer-associated processes. *Biochim Biophys Acta Bioenerg* **1862**, 148338.

291 Szczepkowski TW & Wood JL (1967) The cystathionase-rhodanese system. *Biochim Biophys Acta* **139**, 469–478.

292 Wood JL (1980) Nutritional and protective properties of thiocystine. *Proc Soc Exp Biol Med* **165**, 469–472.

293 Lin J, Akiyama M, Bica I, Long FT, Henderson CF, Goddu RN, Suarez V, Baker B, Ida T, Shinkai Y *et al.* (2019) The uptake and release of polysulfur cysteine species by cells: Physiological and toxicological implications. *Chem Res Toxicol* **32**, 447–455.

294 Ono K (2014) Redox chemistry and chemical biology of H₂S, hydropersulfides, and derived species: implications of their possible biological activity and utility. *Free Radic Biol Med* **77**, 82–94.

295 Abdolrasulnia R & Wood JL (1980) Persulfide properties of thiocystine and related trisulfides. *Bioorg Chem* **9**, 253–260.

296 Vicente JB, Colaço HG, Sarti P, Leandro P & Giuffrè A (2016) S-Adenosyl-l-methionine modulates CO and NO• binding to the human H₂S-generating enzyme cystathionine β-synthase. *J Biol Chem* **291**, 572–581.

297 Taoka S, West M & Banerjee R (1999) Characterization of the heme and pyridoxal phosphate cofactors of human cystathionine beta-synthase reveals nonequivalent active sites. *Biochemistry* **38**, 2738–2744.

298 Cortese-Krott MM, Koning A, Kuhnle GGC, Nagy P, Bianco CL, Pasch A, Wink DA, Fukuto JM, Jackson AA, van Goor H *et al.* (2017) The reactive species interactome: Evolutionary emergence, biological significance, and opportunities for redox metabolomics and personalized medicine. *Antioxid Redox Signal* **27**, 684–712.

299 Ma J & Dasgupta PK (2010) Recent developments in cyanide detection: a review. *Anal Chim Acta* **673**, 117–125.

300 Milazzo S, Ernst E, Lejeune S, Boehm K & Horneber M (2011) Laetrile treatment for cancer. *Cochrane Database Syst Rev* **11**, CD005476.

301 Milazzo S & Horneber M (2015) Laetrile treatment for cancer. *Cochrane Database Syst Rev* **4**, CD005476.

302 Blaheta RA, Nelson K, Haferkamp A & Juengel E (2016) Amygdalin, quackery or cure? *Phytomedicine* **23**, 367–76.

303 Saleem M, Asif J, Asif M & Saleem U (2018) Amygdalin from apricot kernels induces apoptosis and causes cell cycle arrest in cancer cells: an updated review. *Anticancer Agents Med Chem* **18**, 1650–1655.

304 Kousparou CA, Epenetos AA & Deonarain MP (2002) Antibody-guided enzyme therapy of cancer producing cyanide results in necrosis of targeted cells. *Int J Cancer* **99**, 138–48.

305 Gandhirajan RK, Rödder K, Bodnar Y, Pasqual-Melo G, Emmert S, Griguer CE, Weltmann KD & Bekeschus S (2018) Cytochrome C oxidase inhibition and cold plasma-derived oxidants synergize in melanoma cell death induction. *Sci Rep* **8**, 12734.